Bristol Myers Squibb Co (BMY) KPIs and segments
Close on Nov 18, 2026Market cap $121.75BP/E 13.2Yield 4.18%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Bristol Myers Squibb · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026; Q3 2026 ended September 30, 2026)
Nhìn nhanh KPI của Bristol Myers Squibb: 55 chỉ số vận hành, trong đó có Total Revenues — Worldwide, Total Growth Portfolio — Worldwide net revenues và Total Legacy Portfolio — Worldwide net revenues, lấy từ 193 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net product sales($M) | 12,606 | 12,588 | 11,168 | 12,111 | 11,850 | 11,909 | 10,886 | 11,811 | 11,483 | 11,925 | 11,559 | 11,168 | |
Growth Portfolio($M) | 7,662 | 7,560 | 6,227 | 7,393 | 6,857 | 6,596 | 5,563 | 6,363 | 5,812 | 5,596 | 4,792 | 5,259 | |
Legacy Portfolio($M) | 5,415 | 5,422 | 5,277 | 5,109 | 5,365 | 5,673 | 5,638 | 5,979 | 6,080 | 6,605 | 7,073 | 6,218 | |
Eliquis($M) | 4,690 | 4,481 | 4,137 | 3,452 | 3,746 | 3,680 | 3,565 | 3,195 | 3,002 | 3,416 | 3,720 | 2,874 | |
Opdivo($M) | 2,374 | 2,485 | 2,146 | 2,693 | 2,532 | 2,560 | 2,265 | 2,479 | 2,360 | 2,387 | 2,078 | 2,387 | |
Orencia($M) | 983 | 1,034 | 818 | 1,008 | 964 | 963 | 770 | 1,000 | 936 | 948 | 798 | 985 | |
Yervoy($M) | 793 | 769 | 651 | 810 | 739 | 728 | 624 | 675 | 642 | 630 | 583 | 566 | |
Reblozyl($M) | 750 | 735 | 555 | 666 | 615 | 568 | 478 | 547 | 447 | 425 | 354 | 320 | |
Other Growth products($M) | 731 | 653 | 581 | 210 | 651 | 557 | 507 | 527 | 443 | 348 | 325 | 326 | |
Breyanzi($M) | 526 | 484 | 411 | 392 | 359 | 344 | 263 | 263 | 224 | 153 | 107 | 101 | |
Alliance and other revenues($M) | 463 | 385 | 321 | 391 | 372 | 360 | 315 | 409 | 276 | 306 | |||
Camzyos($M) | 420 | 416 | 314 | 354 | 296 | 260 | 159 | 223 | 156 | 139 | 84 | 88 | |
Other revenues($M) | 368 | 281 | 227 | 247 | 241 | 227 | 304 | 160 | 172 | ||||
Opdualag($M) | 367 | 349 | 295 | 350 | 299 | 284 | 252 | 254 | 233 | 235 | 206 | 190 | |
Opdivo Qvantig($M) | 334 | 261 | 163 | 133 | 67 | 30 | 9 | 0 | 0 | 0 | 0 | ||
Revlimid($M) | 303 | 425 | 349 | 602 | 575 | 838 | 936 | 1,339 | 1,412 | 1,353 | 1,669 | 1,450 | |
Zeposia($M) | 168 | 169 | 118 | 159 | 161 | 150 | 107 | 158 | 147 | 151 | 110 | 133 | |
Other Legacy products($M) | 154 | 170 | 156 | 199 | 177 | 223 | 199 | 250 | 225 | 222 | 228 | 231 | |
Pomalyst/Imnovid($M) | 130 | 204 | 513 | 692 | 675 | 708 | 658 | 823 | 898 | 959 | 865 | 890 | |
Abecma($M) | 101 | 137 | 87 | 103 | 105 | 124 | 95 | 82 | 100 | ||||
Sotyktu($M) | 100 | 87 | 69 | 85 | 80 | 70 | 55 | 83 | 66 | 53 | 44 | 63 | |
Alliance revenues($M) | 95 | 104 | 94 | 115 | 125 | 119 | 88 | 124 | 105 | 116 | 134 | 147 | |
Sprycel($M) | 73 | 88 | 73 | 80 | 119 | 120 | 175 | 198 | 290 | 424 | 374 | 526 | |
Abraxane($M) | 65 | 55 | 50 | 84 | 74 | 105 | 105 | 174 | 253 | 231 | 217 | 247 | |
Krazati($M) | 58 | 55 | 50 | 56 | 53 | 48 | 48 | 39 | 34 | 32 | 21 | 0 | |
Cobenfy($M) | 57 | 63 | 56 | 50 | 43 | 35 | 27 | 10 | 0 | 0 | 0 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)6 | |||||||||||||
U S($M) | 9,074 | 8,991 | 7,788 | 8,558 | 8,329 | 8,519 | 7,873 | 8,596 | 8,232 | 8,801 | 8,476 | 7,912 | |
International($M) | 3,592 | 3,664 | 3,444 | 3,635 | 3,602 | 3,481 | 3,110 | 3,396 | 3,389 | 3,224 | 3,190 | 3,036 | |
Other($M) | 403 | 318 | 257 | 309 | 290 | 270 | 218 | 350 | 271 | 176 | 199 | 184 | |
Total Revenues — Worldwide ($M)($M)6 | 13,069 | 12,973 | 11,489 | 12,502 | 12,222 | 12,269 | 11,201 | 12,342 | 11,892 | 12,201 | 11,865 | 11,477 | |
Net Product Sales — Worldwide ($M)($M)1 | 12,606 | 12,588 | 11,168 | 12,111 | 11,850 | 11,909 | 10,886 | 11,811 | 11,483 | 11,925 | 11,559 | 11,168 | |
Net Product Sales — YoY growth (%)(%) | 6.0% | 6.0% | 3.0% | 3.0% | -6.0% | 8.0% | 9.0% | 5.0% | |||||
Alliance and Other Revenues — Worldwide ($M)($M)2 | 463 | 385 | 321 | 391 | 372 | 360 | 315 | 531 | 409 | 276 | 306 | 309 | |
Alliance Revenues ($M)($M) | 95 | 104 | 94 | 115 | 125 | 119 | 88 | 124 | 105 | 116 | 134 | 147 | |
Other Revenues (Royalties, Out-Licensing & Hedging) ($M)($M)1 | 368 | 281 | 227 | 277 | 247 | 241 | 227 | 407 | 304 | 160 | 172 | 162 | |
Revenue Hedging Activities ($M)($M) | -7 | -9 | -15 | 0 | 0 | 0 | |||||||
Total Revenues — United States ($M)($M)1 | 9,074 | 8,991 | 7,788 | 8,558 | 8,329 | 8,519 | 7,873 | 8,596 | 8,232 | 8,801 | 8,476 | 7,912 | |
United States — GAAP revenue growth YoY (%)(%) | 9.0% | 6.0% | -1.0% | 1.0% | -3.0% | -7.0% | 9.0% | 9.0% | 13.0% | 7.0% | 1.0% | ||
Total Revenues — International ($M)($M)4 | 3,995 | 3,982 | 3,701 | 3,944 | 3,893 | 3,750 | 3,328 | 3,746 | 3,660 | 3,400 | 3,389 | 3,565 | |
International — GAAP revenue growth YoY (%)(%) | 3.0% | 6.0% | 11.0% | 5.0% | 6.0% | 10.0% | -2.0% | 5.0% | 7.0% | -1.0% | |||
International — Excl. F/X revenue growth YoY (%)(%) | 4.0% | 5.0% | 4.0% | 1.0% | 3.0% | 8.0% | 2.0% | 9.0% | 11.0% | 6.0% | 5.0% | 1.0% | |
International — F/X impact on YoY revenue growth (%)(%) | -1.0% | 1.0% | 7.0% | 5.0% | 3.0% | 3.0% | -4.0% | -4.0% | -4.0% | -7.0% | -5.0% | ||
Other Region (Unallocated Alliance & Royalty) Revenues ($M)($M) | 403 | 318 | 257 | 309 | 290 | 270 | 218 | 350 | 271 | 176 | 199 | 184 | |
Worldwide — GAAP revenue growth YoY (%)(%) | 7.0% | 6.0% | 3.0% | 1.0% | 3.0% | 1.0% | -6.0% | 8.0% | 8.0% | 9.0% | 5.0% | 1.0% | |
Worldwide — Excl. F/X revenue growth YoY (%)(%) | 7.0% | 5.0% | 1.0% | 2.0% | -4.0% | 9.0% | 10.0% | 11.0% | 6.0% | 1.0% | |||
Total Growth Portfolio — Worldwide net revenues ($M)($M)17 | 7,662 | 7,560 | 6,227 | 7,393 | 6,857 | 6,596 | 5,563 | 6,363 | 5,812 | 5,596 | 4,792 | 5,259 | |
Total Growth Portfolio — U.S. net revenues ($M)($M)1 | 4,951 | 4,974 | 3,872 | 4,958 | 4,432 | 4,348 | 3,633 | 4,172 | 3,800 | 3,785 | 3,083 | 3,498 | |
Total Growth Portfolio — U.S. GAAP revenue growth YoY (%)(%) | 12.0% | 14.0% | 7.0% | 19.0% | 17.0% | 15.0% | 18.0% | 19.0% | 15.0% | 21.0% | 9.0% | ||
Total Growth Portfolio — International net revenues ($M)($M)3 | 2,711 | 2,585 | 2,355 | 2,436 | 2,425 | 2,248 | 1,930 | 2,191 | 2,012 | 1,811 | 1,709 | 1,761 | |
Total Growth Portfolio — International GAAP revenue growth YoY (%)(%) | 12.0% | 15.0% | 22.0% | 11.0% | 20.0% | 24.0% | 13.0% | 24.0% | 22.0% | 11.0% | 8.0% | ||
Total Growth Portfolio — International Excl. F/X revenue growth YoY (%)(%) | 13.0% | 13.0% | 15.0% | 7.0% | 17.0% | 23.0% | 18.0% | 31.0% | 29.0% | 21.0% | 15.0% | ||
Total Growth Portfolio — International F/X impact on YoY growth (%)(%) | -1.0% | 2.0% | 7.0% | 5.0% | 3.0% | 2.0% | -5.0% | -7.0% | -7.0% | -10.0% | -7.0% | ||
Total Growth Portfolio — Worldwide GAAP revenue growth YoY (%)(%) | 12.0% | 15.0% | 12.0% | 16.0% | 18.0% | 18.0% | 16.0% | 21.0% | 18.0% | 18.0% | 8.0% | ||
Total Growth Portfolio — Worldwide Excl. F/X revenue growth YoY (%)(%) | 12.0% | 14.0% | 9.0% | 15.0% | 17.0% | 17.0% | 18.0% | 23.0% | 20.0% | 21.0% | 11.0% | ||
Opdivo (nivolumab — PD-1 Immuno-Oncology) — Worldwide net revenues ($M)($M)4 | 2,374 | 2,485 | 2,146 | 2,693 | 2,532 | 2,560 | 2,265 | 2,479 | 2,360 | 2,387 | 2,078 | 2,387 | |
Opdivo (nivolumab — PD-1 Immuno-Oncology) — U.S. net revenues ($M)($M)1 | 1,345 | 1,417 | 1,159 | 1,611 | 1,454 | 1,506 | 1,332 | 1,423 | 1,366 | 1,406 | 1,155 | 1,401 | |
Opdivo (nivolumab — PD-1 Immuno-Oncology) — U.S. GAAP revenue growth YoY (%)(%) | -8.0% | -6.0% | -13.0% | 13.0% | 6.0% | 7.0% | 15.0% | 2.0% | 2.0% | 15.0% | -10.0% | 12.0% | |
Opdivo (nivolumab — PD-1 Immuno-Oncology) — International net revenues ($M)($M)2 | 1,029 | 1,068 | 988 | 1,082 | 1,077 | 1,053 | 933 | 1,056 | 994 | 981 | 923 | 986 | |
Opdivo (nivolumab — PD-1 Immuno-Oncology) — International GAAP revenue growth YoY (%)(%) | -4.0% | 1.0% | 6.0% | 2.0% | 8.0% | 7.0% | 1.0% | 7.0% | 7.0% | 6.0% | 3.0% | ||
Opdivo (nivolumab — PD-1 Immuno-Oncology) — International Excl. F/X revenue growth YoY (%)(%) | -4.0% | -1.0% | -1.0% | -2.0% | 6.0% | 7.0% | 7.0% | 15.0% | 16.0% | 18.0% | 9.0% | 4.0% | |
Opdivo (nivolumab — PD-1 Immuno-Oncology) — Worldwide GAAP revenue growth YoY (%)(%) | -6.0% | -3.0% | -5.0% | 9.0% | 7.0% | 7.0% | 9.0% | 4.0% | 4.0% | 11.0% | -6.0% | 8.0% | |
Opdivo (nivolumab — PD-1 Immuno-Oncology) — Worldwide Excl. F/X revenue growth YoY (%)(%) | -6.0% | -4.0% | -8.0% | 7.0% | 6.0% | 7.0% | 12.0% | 7.0% | 7.0% | 16.0% | -2.0% | 8.0% | |
Opdivo Qvantig (subcutaneous nivolumab + hyaluronidase-nvhy) — Worldwide net revenues ($M)($M)2 | 334 | 261 | 163 | 133 | 67 | 30 | 9 | 0 | 0 | 0 | 0 | ||
Opdivo Qvantig (subcutaneous nivolumab + hyaluronidase-nvhy) — U.S. net revenues ($M)($M) | 250 | 206 | 131 | 108 | 60 | 28 | 8 | ||||||
Opdivo Qvantig (subcutaneous nivolumab + hyaluronidase-nvhy) — International net revenues ($M)($M) | 84 | 55 | 32 | 25 | 7 | 1 | |||||||
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — Worldwide net revenues ($M)($M)4 | 983 | 1,034 | 818 | 1,008 | 964 | 963 | 770 | 1,000 | 936 | 948 | 798 | 985 | |
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — U.S. net revenues ($M)($M)1 | 754 | 801 | 590 | 749 | 721 | 711 | 555 | 750 | 706 | 742 | 572 | 755 | |
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — U.S. GAAP revenue growth YoY (%)(%) | 5.0% | 13.0% | 6.0% | 2.0% | -4.0% | -3.0% | -1.0% | 7.0% | 4.0% | 8.0% | |||
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — International net revenues ($M)($M)3 | 230 | 233 | 228 | 259 | 243 | 252 | 215 | 250 | 230 | 206 | 226 | 230 | |
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — International GAAP revenue growth YoY (%)(%) | -6.0% | -8.0% | 6.0% | 3.0% | 6.0% | 23.0% | -5.0% | 9.0% | 6.0% | -11.0% | 6.0% | 8.0% | |
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — International Excl. F/X revenue growth YoY (%)(%) | -4.0% | -8.0% | 6.0% | 1.0% | 3.0% | 20.0% | -1.0% | 15.0% | 13.0% | -2.0% | 13.0% | 11.0% | |
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — International F/X impact on YoY growth (%)(%) | -1.0% | 1.0% | 6.0% | 4.0% | 2.0% | 3.0% | -4.0% | -6.0% | -7.0% | -9.0% | -7.0% | -3.0% | |
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — Worldwide GAAP revenue growth YoY (%)(%) | 2.0% | 7.0% | 6.0% | 1.0% | 3.0% | 2.0% | -4.0% | 2.0% | 1.0% | 2.0% | 4.0% | 8.0% | |
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 2.0% | 7.0% | 5.0% | 2.0% | 1.0% | -2.0% | 3.0% | 3.0% | 5.0% | 6.0% | 9.0% | ||
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — Worldwide net revenues ($M)($M)4 | 793 | 769 | 651 | 810 | 739 | 728 | 624 | 675 | 642 | 630 | 583 | 566 | |
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — U.S. net revenues ($M)($M)1 | 482 | 481 | 367 | 525 | 455 | 451 | 394 | 428 | 399 | 404 | 368 | 340 | |
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — U.S. GAAP revenue growth YoY (%)(%) | 6.0% | 7.0% | -7.0% | 23.0% | 14.0% | 12.0% | 7.0% | 26.0% | 11.0% | 10.0% | 18.0% | -1.0% | |
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — International net revenues ($M)($M)3 | 311 | 288 | 284 | 284 | 284 | 277 | 230 | 247 | 243 | 226 | 215 | 226 | |
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — International GAAP revenue growth YoY (%)(%) | 10.0% | 4.0% | 24.0% | 15.0% | 17.0% | 22.0% | 7.0% | 9.0% | 10.0% | 4.0% | 10.0% | ||
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — International Excl. F/X revenue growth YoY (%)(%) | 10.0% | 2.0% | 16.0% | 10.0% | 13.0% | 21.0% | 12.0% | 15.0% | 17.0% | 11.0% | 17.0% | 1.0% | |
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — International F/X impact on YoY growth (%)(%) | -1.0% | 2.0% | 8.0% | 6.0% | 4.0% | 2.0% | -6.0% | -6.0% | -7.0% | -7.0% | -7.0% | -1.0% | |
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — Worldwide GAAP revenue growth YoY (%)(%) | 7.0% | 6.0% | 4.0% | 20.0% | 15.0% | 16.0% | 7.0% | 19.0% | 11.0% | 8.0% | 15.0% | ||
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 8.0% | 5.0% | 2.0% | 18.0% | 14.0% | 15.0% | 9.0% | 22.0% | 13.0% | 10.0% | 18.0% | ||
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — Worldwide net revenues ($M)($M)4 | 750 | 735 | 555 | 666 | 615 | 568 | 478 | 547 | 447 | 425 | 354 | 320 | |
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — U.S. net revenues ($M)($M)1 | 610 | 593 | 440 | 552 | 494 | 453 | 390 | 445 | 358 | 348 | 293 | 270 | |
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — U.S. GAAP revenue growth YoY (%)(%) | 23.0% | 31.0% | 13.0% | 24.0% | 38.0% | 30.0% | 33.0% | 65.0% | 79.0% | 96.0% | 88.0% | 75.0% | |
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — International net revenues ($M)($M)3 | 140 | 142 | 116 | 114 | 121 | 114 | 89 | 102 | 89 | 77 | 61 | 50 | |
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — International GAAP revenue growth YoY (%)(%) | 16.0% | 24.0% | 30.0% | 12.0% | 35.0% | 51.0% | 44.0% | 104.0% | 85.0% | 38.0% | 22.0% | 10.0% | |
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — International Excl. F/X revenue growth YoY (%)(%) | 18.0% | 24.0% | 23.0% | 6.0% | 31.0% | 46.0% | 49.0% | 110.0% | 90.0% | 41.0% | 22.0% | 5.0% | |
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — International F/X impact on YoY growth (%)(%) | -1.0% | 1.0% | 8.0% | 6.0% | 4.0% | 5.0% | -5.0% | -6.0% | -5.0% | -3.0% | 5.0% | ||
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — Worldwide GAAP revenue growth YoY (%)(%) | 22.0% | 29.0% | 16.0% | 22.0% | 37.0% | 34.0% | 35.0% | 71.0% | 80.0% | 82.0% | 72.0% | 61.0% | |
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 22.0% | 29.0% | 15.0% | 21.0% | 37.0% | 33.0% | 36.0% | 72.0% | 81.0% | 82.0% | 72.0% | 60.0% | |
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — Worldwide net revenues ($M)($M)4 | 526 | 484 | 411 | 392 | 359 | 344 | 263 | 263 | 224 | 153 | 107 | 101 | |
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — U.S. net revenues ($M)($M)1 | 359 | 354 | 292 | 284 | 251 | 255 | 204 | 209 | 173 | 122 | 87 | 85 | |
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — U.S. GAAP revenue growth YoY (%)(%) | 43.0% | 39.0% | 43.0% | 37.0% | 45.0% | 110.0% | 133.0% | 146.0% | 125.0% | 47.0% | 50.0% | ||
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — International net revenues ($M)($M)2 | 167 | 131 | 120 | 107 | 109 | 88 | 60 | 54 | 51 | 31 | 20 | 16 | |
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — International GAAP revenue growth YoY (%)(%) | 53.0% | 48.0% | 101.0% | 94.0% | 115.0% | 183.0% | 82.0% | 54.0% | 23.0% | ||||
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — International Excl. F/X revenue growth YoY (%)(%) | 57.0% | 47.0% | 87.0% | 85.0% | 104.0% | 167.0% | 94.0% | 54.0% | 23.0% | ||||
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — Worldwide GAAP revenue growth YoY (%)(%) | 46.0% | 41.0% | 56.0% | 49.0% | 60.0% | 125.0% | 146.0% | 160.0% | 143.0% | 53.0% | 51.0% | 84.0% | |
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 48.0% | 41.0% | 53.0% | 47.0% | 58.0% | 122.0% | 148.0% | 162.0% | 143.0% | 55.0% | 51.0% | 84.0% | |
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — Worldwide net revenues ($M)($M)4 | 367 | 349 | 295 | 350 | 299 | 284 | 252 | 254 | 233 | 235 | 206 | 190 | |
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — U.S. net revenues ($M)($M)1 | 305 | 294 | 246 | 306 | 259 | 252 | 228 | 233 | 216 | 223 | 198 | 186 | |
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — U.S. GAAP revenue growth YoY (%)(%) | 18.0% | 17.0% | 8.0% | 31.0% | 20.0% | 13.0% | 15.0% | 25.0% | 33.0% | 48.0% | 71.0% | 80.0% | |
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — International net revenues ($M)($M)3 | 62 | 55 | 49 | 44 | 40 | 32 | 25 | 21 | 17 | 12 | 8 | 4 | |
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — International GAAP revenue growth YoY (%)(%) | 57.0% | 72.0% | 98.0% | 109.0% | 122.0% | 161.0% | |||||||
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — International Excl. F/X revenue growth YoY (%)(%) | 56.0% | 65.0% | 81.0% | 98.0% | 115.0% | 155.0% | |||||||
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — International F/X impact on YoY growth (%)(%) | 1.0% | 6.0% | 17.0% | 11.0% | 7.0% | 7.0% | |||||||
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — Worldwide GAAP revenue growth YoY (%)(%) | 23.0% | 23.0% | 17.0% | 38.0% | 28.0% | 21.0% | 23.0% | 34.0% | 40.0% | 53.0% | 76.0% | 83.0% | |
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 23.0% | 22.0% | 15.0% | 37.0% | 27.0% | 20.0% | 23.0% | 34.0% | 40.0% | 53.0% | 76.0% | 83.0% | |
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — Worldwide net revenues ($M)($M)4 | 420 | 416 | 314 | 354 | 296 | 260 | 159 | 223 | 156 | 139 | 84 | 88 | |
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — U.S. net revenues ($M)($M)1 | 299 | 310 | 229 | 286 | 238 | 214 | 126 | 201 | 135 | 130 | 77 | 83 | |
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — U.S. GAAP revenue growth YoY (%)(%) | 26.0% | 45.0% | 82.0% | 42.0% | 76.0% | 65.0% | 63.0% | 142.0% | 101.0% | ||||
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — International net revenues ($M)($M)3 | 121 | 105 | 85 | 68 | 57 | 46 | 33 | 22 | 21 | 9 | 7 | 5 | |
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — International GAAP revenue growth YoY (%)(%) | 111.0% | 129.0% | 155.0% | 177.0% | |||||||||
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — International Excl. F/X revenue growth YoY (%)(%) | 109.0% | 124.0% | 137.0% | 168.0% | |||||||||
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — International F/X impact on YoY growth (%)(%) | 2.0% | 5.0% | 18.0% | 9.0% | |||||||||
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — Worldwide GAAP revenue growth YoY (%)(%) | 42.0% | 60.0% | 97.0% | 59.0% | 89.0% | 87.0% | 89.0% | 153.0% | 129.0% | ||||
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 42.0% | 59.0% | 94.0% | 57.0% | 88.0% | 86.0% | 90.0% | 153.0% | 129.0% | ||||
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — Worldwide net revenues ($M)($M)5 | 168 | 169 | 118 | 159 | 161 | 150 | 107 | 158 | 147 | 151 | 110 | 133 | |
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — U.S. net revenues ($M)($M)1 | 115 | 116 | 69 | 113 | 113 | 105 | 61 | 115 | 105 | 111 | 72 | 100 | |
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — U.S. GAAP revenue growth YoY (%)(%) | 2.0% | 11.0% | 14.0% | -2.0% | 8.0% | -5.0% | -16.0% | 15.0% | 11.0% | 52.0% | 41.0% | 74.0% | |
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — International net revenues ($M)($M)3 | 53 | 53 | 49 | 46 | 48 | 46 | 46 | 43 | 42 | 40 | 38 | 33 | |
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — International GAAP revenue growth YoY (%)(%) | 11.0% | 17.0% | 7.0% | 9.0% | 13.0% | 15.0% | 22.0% | 30.0% | 50.0% | 48.0% | 41.0% | 52.0% | |
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — International Excl. F/X revenue growth YoY (%)(%) | 13.0% | 14.0% | -3.0% | 1.0% | 6.0% | 10.0% | 26.0% | 33.0% | 46.0% | 48.0% | 41.0% | 43.0% | |
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — International F/X impact on YoY growth (%)(%) | -2.0% | 2.0% | 10.0% | 9.0% | 6.0% | 5.0% | -4.0% | -3.0% | 4.0% | 9.0% | |||
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — Worldwide GAAP revenue growth YoY (%)(%) | 5.0% | 12.0% | 11.0% | 1.0% | 9.0% | 15.0% | -3.0% | 19.0% | 20.0% | 51.0% | 41.0% | 68.0% | |
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 5.0% | 12.0% | 7.0% | -1.0% | 7.0% | -2.0% | -2.0% | 20.0% | 19.0% | 51.0% | 41.0% | 66.0% | |
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — Worldwide F/X impact on YoY growth (%)(%) | -1.0% | 1.0% | 4.0% | 2.0% | 2.0% | 1.0% | -1.0% | -1.0% | 1.0% | 2.0% | |||
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — Worldwide net revenues ($M)($M)4 | 100 | 87 | 69 | 85 | 80 | 70 | 55 | 83 | 66 | 53 | 44 | 63 | |
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — U.S. net revenues ($M)($M)1 | 63 | 51 | 35 | 56 | 51 | 43 | 32 | 64 | 51 | 41 | 34 | 56 | |
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — U.S. GAAP revenue growth YoY (%)(%) | 25.0% | 19.0% | 10.0% | -13.0% | 5.0% | -5.0% | 14.0% | -18.0% | 71.0% | ||||
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — International net revenues ($M)($M)3 | 37 | 36 | 33 | 30 | 29 | 27 | 23 | 19 | 15 | 12 | 10 | 7 | |
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — International GAAP revenue growth YoY (%)(%) | 27.0% | 30.0% | 43.0% | 71.0% | 91.0% | 116.0% | 138.0% | 171.0% | |||||
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — International Excl. F/X revenue growth YoY (%)(%) | 26.0% | 27.0% | 34.0% | 65.0% | 87.0% | 109.0% | 146.0% | 171.0% | 71.0% | ||||
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — International F/X impact on YoY growth (%)(%) | 1.0% | 2.0% | 9.0% | 6.0% | 4.0% | 7.0% | -9.0% | ||||||
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — Worldwide GAAP revenue growth YoY (%)(%) | 26.0% | 23.0% | 24.0% | 4.0% | 21.0% | 31.0% | 27.0% | 32.0% | |||||
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 25.0% | 23.0% | 20.0% | 3.0% | 20.0% | 29.0% | 29.0% | 32.0% | -18.0% | ||||
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — Worldwide net revenues ($M)($M)4 | 58 | 55 | 50 | 56 | 53 | 48 | 48 | 39 | 34 | 32 | 21 | 0 | |
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — U.S. net revenues ($M)($M)1 | 54 | 47 | 46 | 52 | 48 | 47 | 44 | 36 | 32 | 29 | 21 | ||
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — U.S. GAAP revenue growth YoY (%)(%) | 11.0% | 1.0% | 4.0% | 45.0% | 52.0% | 58.0% | 116.0% | ||||||
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — International net revenues ($M)($M) | 5 | 8 | 3 | 3 | 5 | 2 | 4 | 3 | 2 | 3 | |||
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — Worldwide GAAP revenue growth YoY (%)(%) | 10.0% | 14.0% | 4.0% | 41.0% | 58.0% | 51.0% | 125.0% | ||||||
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 10.0% | 14.0% | 3.0% | 41.0% | 57.0% | 51.0% | 125.0% | ||||||
Cobenfy (xanomeline and trospium chloride — Schizophrenia) — Worldwide net revenues ($M)($M)3 | 57 | 63 | 56 | 50 | 43 | 35 | 27 | 10 | 0 | 0 | 0 | ||
Cobenfy (xanomeline and trospium chloride — Schizophrenia) — U.S. net revenues ($M)($M)1 | 55 | 60 | 56 | 50 | 43 | 35 | 27 | 10 | |||||
Cobenfy (xanomeline and trospium chloride — Schizophrenia) — U.S. GAAP revenue growth YoY (%)(%) | 29.0% | 73.0% | 107.0% | ||||||||||
Cobenfy (xanomeline and trospium chloride — Schizophrenia) — Worldwide GAAP revenue growth YoY (%)(%) | 33.0% | 81.0% | 107.0% | ||||||||||
Cobenfy (xanomeline and trospium chloride — Schizophrenia) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 33.0% | 81.0% | 107.0% | ||||||||||
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — Worldwide net revenues ($M)($M)8 | 731 | 653 | 581 | 210 | 651 | 557 | 507 | 527 | 443 | 348 | 325 | 326 | |
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — U.S. net revenues ($M)($M)1 | 261 | 244 | 212 | 212 | 246 | 248 | 233 | 199 | 182 | 175 | 154 | 165 | |
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — U.S. GAAP revenue growth YoY (%)(%) | 6.0% | -1.0% | -9.0% | 6.0% | 8.0% | 15.0% | 13.0% | 13.0% | 15.0% | 4.0% | 3.0% | ||
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — International net revenues ($M)($M)2 | 470 | 409 | 369 | 325 | 405 | 309 | 274 | 328 | 261 | 173 | 171 | 160 | |
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — International GAAP revenue growth YoY (%)(%) | 16.0% | 32.0% | 35.0% | -1.0% | 22.0% | 56.0% | 34.0% | 104.0% | 61.0% | 30.0% | 26.0% | ||
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — International Excl. F/X revenue growth YoY (%)(%) | 17.0% | 32.0% | 32.0% | -3.0% | 21.0% | 55.0% | 35.0% | 106.0% | 64.0% | 35.0% | 30.0% | ||
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — Worldwide GAAP revenue growth YoY (%)(%) | 12.0% | 17.0% | 15.0% | 2.0% | 16.0% | 35.0% | 24.0% | 58.0% | 39.0% | 16.0% | 14.0% | ||
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 13.0% | 17.0% | 13.0% | 1.0% | 16.0% | 35.0% | 25.0% | 59.0% | 41.0% | 18.0% | 16.0% | ||
Abecma (idecabtagene vicleucel — BCMA CAR-T) — Worldwide net revenues ($M)($M)5 | 101 | 137 | 87 | 103 | 105 | 124 | 95 | 82 | 100 | ||||
Abecma (idecabtagene vicleucel — BCMA CAR-T) — U.S. net revenues ($M)($M)1 | 52 | 51 | 47 | 59 | 59 | 77 | 54 | 52 | 56 | ||||
Abecma (idecabtagene vicleucel — BCMA CAR-T) — U.S. GAAP revenue growth YoY (%)(%) | -12.0% | -34.0% | -14.0% | 13.0% | 5.0% | 12.0% | -53.0% | -56.0% | -40.0% | ||||
Abecma (idecabtagene vicleucel — BCMA CAR-T) — International net revenues ($M)($M)3 | 49 | 86 | 40 | 45 | 46 | 47 | 41 | 30 | 44 | ||||
Abecma (idecabtagene vicleucel — BCMA CAR-T) — International GAAP revenue growth YoY (%)(%) | 7.0% | 80.0% | -1.0% | 47.0% | 5.0% | 96.0% | 3.0% | 42.0% | |||||
Abecma (idecabtagene vicleucel — BCMA CAR-T) — International Excl. F/X revenue growth YoY (%)(%) | 1.0% | 71.0% | -7.0% | 54.0% | 5.0% | 100.0% | 7.0% | 39.0% | |||||
Abecma (idecabtagene vicleucel — BCMA CAR-T) — International F/X impact on YoY growth (%)(%) | 6.0% | 9.0% | 5.0% | -6.0% | -4.0% | -4.0% | 3.0% | ||||||
Abecma (idecabtagene vicleucel — BCMA CAR-T) — Worldwide GAAP revenue growth YoY (%)(%) | -4.0% | 9.0% | -8.0% | 26.0% | 5.0% | 33.0% | -28.0% | -44.0% | -20.0% | ||||
Abecma (idecabtagene vicleucel — BCMA CAR-T) — Worldwide Excl. F/X revenue growth YoY (%)(%) | -6.0% | 6.0% | -11.0% | 28.0% | 5.0% | 34.0% | -27.0% | -44.0% | -21.0% | ||||
Abecma (idecabtagene vicleucel — BCMA CAR-T) — Worldwide F/X impact on YoY growth (%)(%) | 3.0% | 4.0% | 2.0% | -2.0% | -1.0% | -1.0% | 1.0% | ||||||
Augtyro (repotrectinib — ROS1/NTRK TKI) — Worldwide net revenues ($M)($M)1 | 15 | 10 | 7 | 6 | 1 | ||||||||
Augtyro (repotrectinib — ROS1/NTRK TKI) — U.S. net revenues ($M)($M) | 13 | 10 | 7 | 6 | 1 | ||||||||
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — Worldwide net revenues ($M)($M)4 | 29 | ||||||||||||
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — U.S. net revenues ($M)($M)1 | 19 | ||||||||||||
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — U.S. GAAP revenue growth YoY (%)(%) | 12.0% | ||||||||||||
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — International net revenues ($M)($M) | 10 | ||||||||||||
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — Worldwide GAAP revenue growth YoY (%)(%) | 26.0% | ||||||||||||
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 26.0% | ||||||||||||
Onureg (oral azacitidine — AML Maintenance) — Worldwide net revenues ($M)($M)5 | 47 | ||||||||||||
Onureg (oral azacitidine — AML Maintenance) — U.S. net revenues ($M)($M)1 | 31 | ||||||||||||
Onureg (oral azacitidine — AML Maintenance) — U.S. GAAP revenue growth YoY (%)(%) | 15.0% | ||||||||||||
Onureg (oral azacitidine — AML Maintenance) — International net revenues ($M)($M)2 | 16 | ||||||||||||
Onureg (oral azacitidine — AML Maintenance) — International GAAP revenue growth YoY (%)(%) | 60.0% | ||||||||||||
Onureg (oral azacitidine — AML Maintenance) — International Excl. F/X revenue growth YoY (%)(%) | 50.0% | ||||||||||||
Onureg (oral azacitidine — AML Maintenance) — Worldwide GAAP revenue growth YoY (%)(%) | 27.0% | ||||||||||||
Onureg (oral azacitidine — AML Maintenance) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 24.0% | ||||||||||||
Onureg (oral azacitidine — AML Maintenance) — Worldwide F/X impact on YoY growth (%)(%) | 3.0% | ||||||||||||
Total Legacy Portfolio — Worldwide net revenues ($M)($M)10 | 5,415 | 5,422 | 5,277 | 5,109 | 5,365 | 5,673 | 5,638 | 5,979 | 6,080 | 6,605 | 7,073 | 6,218 | |
Total Legacy Portfolio — U.S. net revenues ($M)($M)1 | 4,123 | 4,017 | 3,916 | 3,600 | 3,897 | 4,171 | 4,240 | 4,424 | 4,432 | 5,016 | 5,393 | 4,414 | |
Total Legacy Portfolio — U.S. GAAP revenue growth YoY (%)(%) | 6.0% | -4.0% | -8.0% | -19.0% | -12.0% | -17.0% | -21.0% | 4.0% | 7.0% | 5.0% | |||
Total Legacy Portfolio — International net revenues ($M)($M)3 | 1,292 | 1,405 | 1,361 | 1,509 | 1,468 | 1,503 | 1,398 | 1,555 | 1,648 | 1,589 | 1,680 | 1,804 | |
Total Legacy Portfolio — International GAAP revenue growth YoY (%)(%) | -12.0% | -7.0% | -3.0% | -3.0% | -11.0% | -6.0% | -17.0% | -14.0% | -7.0% | -11.0% | -7.0% | ||
Total Legacy Portfolio — International Excl. F/X revenue growth YoY (%)(%) | -10.0% | -7.0% | -10.0% | -8.0% | -14.0% | -9.0% | -14.0% | -12.0% | -6.0% | -8.0% | -4.0% | ||
Total Legacy Portfolio — International F/X impact on YoY growth (%)(%) | -2.0% | 1.0% | 7.0% | 5.0% | 3.0% | 4.0% | -3.0% | -2.0% | -1.0% | -3.0% | -3.0% | ||
Total Legacy Portfolio — Worldwide GAAP revenue growth YoY (%)(%) | 1.0% | -4.0% | -6.0% | -15.0% | -12.0% | -14.0% | -20.0% | -4.0% | 1.0% | 2.0% | 2.0% | ||
Total Legacy Portfolio — Worldwide Excl. F/X revenue growth YoY (%)(%) | 1.0% | -5.0% | -8.0% | -16.0% | -13.0% | -15.0% | -20.0% | -3.0% | 1.0% | 3.0% | 3.0% | ||
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — Worldwide net revenues ($M)($M)4 | 4,690 | 4,481 | 4,137 | 3,452 | 3,746 | 3,680 | 3,565 | 3,195 | 3,002 | 3,416 | 3,720 | 2,874 | |
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — U.S. net revenues ($M)($M)1 | 3,653 | 3,357 | 3,077 | 2,308 | 2,631 | 2,654 | 2,646 | 2,221 | 2,045 | 2,544 | 2,821 | 1,872 | |
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — U.S. GAAP revenue growth YoY (%)(%) | 39.0% | 27.0% | 16.0% | 4.0% | 29.0% | 4.0% | -6.0% | 19.0% | 15.0% | 10.0% | 12.0% | 11.0% | |
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — International net revenues ($M)($M)3 | 1,037 | 1,124 | 1,059 | 1,144 | 1,115 | 1,027 | 919 | 974 | 957 | 872 | 899 | 1,002 | |
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — International GAAP revenue growth YoY (%)(%) | -7.0% | 9.0% | 15.0% | 18.0% | 16.0% | 18.0% | 2.0% | -3.0% | 3.0% | -2.0% | 1.0% | ||
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — International Excl. F/X revenue growth YoY (%)(%) | -5.0% | 7.0% | 5.0% | 9.0% | 11.0% | 12.0% | 5.0% | -2.0% | 2.0% | 7.0% | 1.0% | -3.0% | |
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — International F/X impact on YoY growth (%)(%) | -2.0% | 2.0% | 10.0% | 8.0% | 6.0% | 6.0% | -3.0% | -1.0% | 1.0% | -2.0% | -1.0% | 4.0% | |
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — Worldwide GAAP revenue growth YoY (%)(%) | 25.0% | 22.0% | 16.0% | 8.0% | 25.0% | 8.0% | -4.0% | 11.0% | 11.0% | 7.0% | 9.0% | 7.0% | |
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 26.0% | 21.0% | 13.0% | 6.0% | 23.0% | 6.0% | -3.0% | 11.0% | 11.0% | 7.0% | 9.0% | 6.0% | |
Revlimid (lenalidomide — Multiple Myeloma & MDS) — Worldwide net revenues ($M)($M)4 | 303 | 425 | 349 | 602 | 575 | 838 | 936 | 1,339 | 1,412 | 1,353 | 1,669 | 1,450 | |
Revlimid (lenalidomide — Multiple Myeloma & MDS) — U.S. net revenues ($M)($M)1 | 239 | 352 | 278 | 508 | 485 | 732 | 809 | 1,169 | 1,212 | 1,165 | 1,453 | 1,244 | |
Revlimid (lenalidomide — Multiple Myeloma & MDS) — U.S. GAAP revenue growth YoY (%)(%) | -51.0% | -52.0% | -66.0% | -57.0% | -60.0% | -37.0% | -44.0% | -6.0% | -4.0% | -5.0% | -38.0% | ||
Revlimid (lenalidomide — Multiple Myeloma & MDS) — International net revenues ($M)($M)3 | 63 | 72 | 71 | 94 | 89 | 106 | 127 | 170 | 200 | 188 | 216 | 206 | |
Revlimid (lenalidomide — Multiple Myeloma & MDS) — International GAAP revenue growth YoY (%)(%) | -29.0% | -32.0% | -44.0% | -45.0% | -55.0% | -44.0% | -41.0% | -17.0% | -9.0% | -24.0% | -5.0% | -21.0% | |
Revlimid (lenalidomide — Multiple Myeloma & MDS) — International Excl. F/X revenue growth YoY (%)(%) | -28.0% | -30.0% | -45.0% | -45.0% | -56.0% | -44.0% | -39.0% | -15.0% | -6.0% | -20.0% | -1.0% | -20.0% | |
Revlimid (lenalidomide — Multiple Myeloma & MDS) — International F/X impact on YoY growth (%)(%) | -1.0% | -2.0% | 1.0% | 1.0% | -3.0% | -2.0% | -3.0% | -4.0% | -4.0% | -1.0% | |||
Revlimid (lenalidomide — Multiple Myeloma & MDS) — Worldwide GAAP revenue growth YoY (%)(%) | -47.0% | -49.0% | -63.0% | -55.0% | -59.0% | -38.0% | -44.0% | -8.0% | -1.0% | -8.0% | -5.0% | -36.0% | |
Revlimid (lenalidomide — Multiple Myeloma & MDS) — Worldwide Excl. F/X revenue growth YoY (%)(%) | -47.0% | -49.0% | -63.0% | -55.0% | -59.0% | -38.0% | -44.0% | -7.0% | -1.0% | -7.0% | -4.0% | -36.0% | |
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — Worldwide net revenues ($M)($M)4 | 130 | 204 | 513 | 692 | 675 | 708 | 658 | 823 | 898 | 959 | 865 | 890 | |
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — U.S. net revenues ($M)($M)1 | 72 | 131 | 439 | 624 | 596 | 584 | 537 | 685 | 697 | 716 | 597 | 627 | |
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — U.S. GAAP revenue growth YoY (%)(%) | -88.0% | -78.0% | -18.0% | -9.0% | -15.0% | -18.0% | -10.0% | 9.0% | 15.0% | 27.0% | 10.0% | 1.0% | |
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — International net revenues ($M)($M)3 | 58 | 73 | 74 | 67 | 79 | 124 | 122 | 138 | 201 | 243 | 268 | 263 | |
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — International GAAP revenue growth YoY (%)(%) | -27.0% | -41.0% | -39.0% | -51.0% | -61.0% | -49.0% | -55.0% | -48.0% | -24.0% | -14.0% | -8.0% | 2.0% | |
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — International Excl. F/X revenue growth YoY (%)(%) | -23.0% | -38.0% | -40.0% | -51.0% | -61.0% | -51.0% | -53.0% | -47.0% | -24.0% | -11.0% | -7.0% | 1.0% | |
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — International F/X impact on YoY growth (%)(%) | -4.0% | -3.0% | 1.0% | 1.0% | 2.0% | -1.0% | -1.0% | -3.0% | -1.0% | 2.0% | |||
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — Worldwide GAAP revenue growth YoY (%)(%) | -81.0% | -71.0% | -22.0% | -16.0% | -25.0% | -26.0% | -24.0% | -8.0% | 3.0% | 13.0% | 4.0% | 1.0% | |
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — Worldwide Excl. F/X revenue growth YoY (%)(%) | -80.0% | -71.0% | -22.0% | -16.0% | -25.0% | -27.0% | -24.0% | -7.0% | 3.0% | 14.0% | 4.0% | 1.0% | |
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — Worldwide net revenues ($M)($M)4 | 73 | 88 | 73 | 80 | 119 | 120 | 175 | 198 | 290 | 424 | 374 | 526 | |
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — U.S. net revenues ($M)($M)1 | 43 | 52 | 36 | 36 | 69 | 68 | 126 | 135 | 225 | 341 | 282 | 411 | |
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — U.S. GAAP revenue growth YoY (%)(%) | -38.0% | -23.0% | -71.0% | -74.0% | -69.0% | -80.0% | -56.0% | -67.0% | -44.0% | 6.0% | -2.0% | ||
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — International net revenues ($M)($M)3 | 30 | 35 | 37 | 44 | 49 | 52 | 49 | 63 | 65 | 83 | 92 | 115 | |
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — International GAAP revenue growth YoY (%)(%) | -39.0% | -32.0% | -25.0% | -30.0% | -24.0% | -38.0% | -47.0% | -45.0% | -45.0% | -39.0% | -34.0% | -32.0% | |
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — International Excl. F/X revenue growth YoY (%)(%) | -37.0% | -30.0% | -26.0% | -31.0% | -25.0% | -38.0% | -43.0% | -41.0% | -42.0% | -34.0% | -30.0% | -31.0% | |
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — International F/X impact on YoY growth (%)(%) | -2.0% | -2.0% | 1.0% | 1.0% | 1.0% | -3.0% | -4.0% | -3.0% | -5.0% | -4.0% | -1.0% | ||
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — Worldwide GAAP revenue growth YoY (%)(%) | -38.0% | -27.0% | -58.0% | -60.0% | -59.0% | -72.0% | -53.0% | -62.0% | -44.0% | -7.0% | -13.0% | -9.0% | |
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — Worldwide Excl. F/X revenue growth YoY (%)(%) | -38.0% | -26.0% | -59.0% | -60.0% | -59.0% | -72.0% | -53.0% | -61.0% | -43.0% | -6.0% | -11.0% | -9.0% | |
Abraxane (nab-paclitaxel — Solid Tumors) — Worldwide net revenues ($M)($M)4 | 65 | 55 | 50 | 84 | 74 | 105 | 105 | 174 | 253 | 231 | 217 | 247 | |
Abraxane (nab-paclitaxel — Solid Tumors) — U.S. net revenues ($M)($M)1 | 9 | 12 | 12 | 20 | 24 | 33 | 40 | 91 | 151 | 154 | 145 | 176 | |
Abraxane (nab-paclitaxel — Solid Tumors) — U.S. GAAP revenue growth YoY (%)(%) | -61.0% | -62.0% | -71.0% | -78.0% | -84.0% | -79.0% | -72.0% | -48.0% | -15.0% | -18.0% | -10.0% | 53.0% | |
Abraxane (nab-paclitaxel — Solid Tumors) — International net revenues ($M)($M)2 | 56 | 43 | 38 | 64 | 50 | 72 | 65 | 83 | 102 | 77 | 72 | 71 | |
Abraxane (nab-paclitaxel — Solid Tumors) — International GAAP revenue growth YoY (%)(%) | 10.0% | -40.0% | -42.0% | -24.0% | -50.0% | -7.0% | -10.0% | 17.0% | 24.0% | 8.0% | -8.0% | 11.0% | |
Abraxane (nab-paclitaxel — Solid Tumors) — International Excl. F/X revenue growth YoY (%)(%) | 11.0% | -40.0% | -43.0% | -23.0% | -49.0% | -5.0% | -6.0% | 28.0% | 37.0% | 25.0% | 10.0% | 22.0% | |
Abraxane (nab-paclitaxel — Solid Tumors) — Worldwide GAAP revenue growth YoY (%)(%) | -13.0% | -47.0% | -53.0% | -52.0% | -71.0% | -55.0% | -52.0% | -30.0% | -3.0% | -10.0% | -9.0% | 38.0% | |
Abraxane (nab-paclitaxel — Solid Tumors) — Worldwide Excl. F/X revenue growth YoY (%)(%) | -12.0% | -47.0% | -54.0% | -52.0% | -70.0% | -54.0% | -50.0% | -26.0% | 1.0% | -6.0% | -3.0% | 42.0% | |
Other Legacy Products (Mature Brands) — Worldwide net revenues ($M)($M)4 | 154 | 170 | 156 | 199 | 177 | 223 | 199 | 250 | 225 | 222 | 228 | 231 | |
Other Legacy Products (Mature Brands) — U.S. net revenues ($M)($M)1 | 106 | 112 | 74 | 104 | 92 | 100 | 82 | 123 | 102 | 96 | 95 | 84 | |
Other Legacy Products (Mature Brands) — U.S. GAAP revenue growth YoY (%)(%) | 15.0% | 12.0% | -10.0% | -13.0% | -11.0% | 5.0% | -14.0% | 46.0% | 17.0% | 16.0% | 19.0% | ||
Other Legacy Products (Mature Brands) — International net revenues ($M)($M)2 | 49 | 58 | 82 | 96 | 85 | 123 | 116 | 127 | 123 | 126 | 133 | 147 | |
Other Legacy Products (Mature Brands) — International GAAP revenue growth YoY (%)(%) | -43.0% | -53.0% | -30.0% | -27.0% | -29.0% | -4.0% | -10.0% | -14.0% | -18.0% | -24.0% | -20.0% | ||
Other Legacy Products (Mature Brands) — International Excl. F/X revenue growth YoY (%)(%) | -42.0% | -53.0% | -32.0% | -28.0% | -30.0% | -5.0% | -8.0% | -15.0% | -19.0% | -19.0% | -17.0% | ||
Other Legacy Products (Mature Brands) — Worldwide GAAP revenue growth YoY (%)(%) | -13.0% | -24.0% | -21.0% | -20.0% | -21.0% | -1.0% | -12.0% | 8.0% | -5.0% | -10.0% | -7.0% | ||
Other Legacy Products (Mature Brands) — Worldwide Excl. F/X revenue growth YoY (%)(%) | -13.0% | -24.0% | -23.0% | -21.0% | -21.0% | -1.0% | -11.0% | 7.0% | -5.0% | -8.0% | -6.0% | ||
Historical Classification (Pre-2024): Total In-Line & New Product Portfolio — Worldwide net revenues ($M)($M)7 | 9,780 | ||||||||||||
Historical Classification (Pre-2024): Total In-Line & New Product Portfolio — International net revenues ($M)1 | |||||||||||||
Historical Classification (Pre-2024): Total In-Line & New Product Portfolio — International GAAP revenue growth YoY (%)(%) | 1.0% | ||||||||||||
Historical Classification (Pre-2024): Total In-Line & New Product Portfolio — Worldwide GAAP revenue growth YoY (%)(%) | 9.0% | ||||||||||||
Historical Classification (Pre-2024): Total In-Line & New Product Portfolio — Worldwide Excl. F/X revenue growth YoY (%)(%) | 9.0% | ||||||||||||
Total In-Line Products (Pre-2024 Classification) — Worldwide net revenues ($M)($M)4 | 8,708 | ||||||||||||
Total In-Line Products (Pre-2024 Classification) — U.S. net revenues ($M)($M)1 | 5,670 | ||||||||||||
Total In-Line Products (Pre-2024 Classification) — U.S. GAAP revenue growth YoY (%)(%) | 8.0% | ||||||||||||
Total In-Line Products (Pre-2024 Classification) — International net revenues ($M)($M)1 | 3,038 | ||||||||||||
Total In-Line Products (Pre-2024 Classification) — International GAAP revenue growth YoY (%)(%) | -1.0% | ||||||||||||
Total In-Line Products (Pre-2024 Classification) — Worldwide GAAP revenue growth YoY (%)(%) | 5.0% | ||||||||||||
Total In-Line Products (Pre-2024 Classification) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 5.0% | ||||||||||||
Total New Product Portfolio (Pre-2024 Classification) — Worldwide net revenues ($M)($M)5 | 1,072 | ||||||||||||
Total New Product Portfolio (Pre-2024 Classification) — U.S. net revenues ($M)($M)1 | 894 | ||||||||||||
Total New Product Portfolio (Pre-2024 Classification) — U.S. GAAP revenue growth YoY (%)(%) | 71.0% | ||||||||||||
Total New Product Portfolio (Pre-2024 Classification) — International net revenues ($M)($M)2 | 178 | ||||||||||||
Total New Product Portfolio (Pre-2024 Classification) — International GAAP revenue growth YoY (%)(%) | 45.0% | ||||||||||||
Total New Product Portfolio (Pre-2024 Classification) — International Excl. F/X revenue growth YoY (%)(%) | 39.0% | ||||||||||||
Total New Product Portfolio (Pre-2024 Classification) — Worldwide GAAP revenue growth YoY (%)(%) | 66.0% | ||||||||||||
Total New Product Portfolio (Pre-2024 Classification) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 65.0% | ||||||||||||
Total New Product Portfolio (Pre-2024 Classification) — Worldwide F/X impact on YoY growth (%)(%) | 1.0% | ||||||||||||
Mature and Other Products (Pre-2024 Classification) — Worldwide net revenues ($M)($M)3 | 480 | ||||||||||||
Mature and Other Products (Pre-2024 Classification) — International net revenues ($M)1 | |||||||||||||
Mature and Other Products (Pre-2024 Classification) — International GAAP revenue growth YoY (%)(%) | -6.0% | ||||||||||||
Mature and Other Products (Pre-2024 Classification) — Worldwide Excl. F/X revenue growth YoY (%)(%) | 1.0% | ||||||||||||
Mature and Other Products (Pre-2024 Classification) — Worldwide F/X impact on YoY growth (%)(%) | -1.0% | ||||||||||||
Total Recent LOE Products (Pre-2024 Classification) — Worldwide net revenues ($M)($M)4 | 1,697 | ||||||||||||
Total Recent LOE Products (Pre-2024 Classification) — U.S. net revenues ($M)($M)1 | 1,439 | ||||||||||||
Total Recent LOE Products (Pre-2024 Classification) — U.S. GAAP revenue growth YoY (%)(%) | -33.0% | ||||||||||||
Total Recent LOE Products (Pre-2024 Classification) — International net revenues ($M)($M)1 | 258 | ||||||||||||
Total Recent LOE Products (Pre-2024 Classification) — International Excl. F/X revenue growth YoY (%)(%) | -11.0% | ||||||||||||
Total Recent LOE Products (Pre-2024 Classification) — Worldwide GAAP revenue growth YoY (%)(%) | -30.0% | ||||||||||||
Total Recent LOE Products (Pre-2024 Classification) — Worldwide Excl. F/X revenue growth YoY (%)(%) | -30.0% | ||||||||||||
Gross Product Sales ($M)($M)2 | 17,965 | 18,179 | 16,926 | 35,015 | 22,494 | 22,181 | 19,874 | 19,123 | 21,223 | 20,780 | 19,295 | 12,381 | |
Gross Product Sales — YoY change (%)(%) | -20.0% | -18.0% | -15.0% | 6.0% | 7.0% | 3.0% | 14.0% | 15.0% | 12.0% | ||||
Total Gross-to-Net (GTN) Adjustments ($M)($M)6 | -5,358 | -5,592 | -5,758 | -24,621 | -10,644 | -10,272 | -8,988 | -6,990 | -9,740 | -8,855 | -7,736 | -3,570 | |
Charge-Backs and Cash Discounts ($M)($M)1 | -2,268 | -2,372 | -2,467 | -6,959 | -3,475 | -3,407 | -2,958 | -1,670 | -2,967 | -2,843 | -2,556 | -778 | |
Charge-Backs and Cash Discounts — YoY change (%)(%) | -35.0% | -30.0% | -17.0% | 17.0% | 20.0% | 16.0% | 25.0% | 25.0% | 22.0% | ||||
Medicaid and Medicare Rebates ($M)($M)1 | -1,649 | -1,759 | -1,875 | -12,727 | -4,887 | -4,516 | -3,840 | -3,307 | -4,577 | -3,864 | -3,084 | -1,886 | |
Medicaid and Medicare Rebates — YoY change (%)(%) | -66.0% | -61.0% | -51.0% | 7.0% | 17.0% | 25.0% | 23.0% | 23.0% | 24.0% | ||||
Other Rebates, Returns, Discounts and Adjustments ($M)($M)1 | -1,441 | -1,460 | -1,416 | -4,936 | -2,281 | -2,348 | -2,190 | -2,013 | -2,196 | -2,148 | -2,096 | -906 | |
Other Rebates, Returns, Discounts & Adjustments — YoY change (%)(%) | -37.0% | -38.0% | -35.0% | 4.0% | 9.0% | 4.0% | 16.0% | 21.0% | 26.0% | ||||
U.S. Gross-to-Net Adjustments (Disclosed in Note 2 Footnote) ($M)($M) | 4,400 | 4,700 | 4,800 | 10,500 | 9,800 | 9,500 | 8,200 | 9,700 | 8,900 | 8,000 | 6,900 | 7,700 | |
Net Reduction/(Increase) to GTN Provisions from Prior-Period Sales ($M)($M) | 125 | 88 | -21 | 67 | 87 | 42 | 289 | 56 | 42 | -19 | 80 | 18 | |
Total GTN Adjustments — YoY change (%)(%) | -50.0% | -46.0% | -36.0% | 9.0% | 16.0% | 16.0% | 22.0% | 23.0% | 24.0% | ||||
Gross-to-Net (GTN) Adjustments Percentage — Total Company (%)(%)2 | 30.0% | 30.0% | 34.0% | 47.0% | 46.0% | 45.0% | 46.0% | 42.0% | 40.0% | ||||
U.S. GTN Adjustments Percentage (%)(%) | 32.0% | 34.0% | 38.0% | 54.0% | 52.0% | 51.0% | 52.0% | 48.0% | 45.0% | ||||
Non-U.S. (International) GTN Adjustments Percentage (%)(%) | 22.0% | 20.0% | 21.0% | 18.0% | 19.0% | 21.0% | 20.0% | 20.0% | 21.0% | ||||
Balance Sheet Accrued Rebates and Returns Liability (Current Liabilities) ($M)($M)1 | 4,915 | 5,654 | 5,301 | 8,844 | 11,240 | 9,539 | 8,472 | 9,021 | 9,608 | 7,686 | 6,967 | 7,680 | |
Cash Discounts & Charge-Backs Allowance Against Trade Receivables ($M)($M) | 782 | 826 | 857 | 1,720 | 988 | 949 | 824 | 900 | 730 | 686 | 598 | 646 | |
Top 3 U.S. Wholesalers — Combined Share of Trade Accounts Receivable (%)(%)1 | 71.0% | 71.0% | 70.0% | 75.0% | 74.0% | ||||||||
Non-Recourse Factoring — Trade Accounts Receivable Sold ($M)($M) | 21 | 31 | 37 | 93 | 120 | 72 | 75 | 90 | 83 | 75 | 229 | 231 | |
Research and Development Expense — Total GAAP ($M)($M)5 | 2,365 | 2,959 | 2,649 | 2,586 | 2,528 | 2,580 | 2,257 | 3,191 | 2,374 | 2,899 | 2,695 | 2,478 | |
Drug Development Expense (Clinical Trials & Late-Stage Development) ($M)($M) | 1,140 | 1,106 | 1,127 | 1,223 | 1,151 | 1,095 | 1,081 | 1,222 | 1,094 | 1,096 | 1,083 | ||
Research and Discovery Expense (Early-Stage Discovery & Preclinical) ($M)($M) | 288 | 274 | 293 | 423 | 313 | 291 | 314 | 479 | 323 | 336 | 384 | ||
Other Research and Development Expense ($M)($M) | 937 | 1,579 | 1,229 | 940 | 1,063 | 1,195 | 861 | 1,490 | 957 | 1,467 | 1,228 | ||
Acquired In-Process Research and Development (Acquired IPR&D) Line Item ($M)($M) | 1,558 | 0 | 94 | 1,393 | 633 | 1,508 | 188 | 30 | 262 | 132 | 12,949 | 600 | |
Accrued Research and Development Liability (Current Liabilities) ($M)($M) | 1,793 | 1,562 | 1,514 | 1,434 | 1,397 | 1,384 | 1,389 | 1,366 | 1,300 | 1,231 | 1,256 | 1,257 | |
Collaborative Arrangements — Total Revenues Recognized ($M)($M)1 | 4,795 | 4,588 | 4,242 | 3,593 | 3,880 | 3,840 | 3,723 | 3,388 | 3,196 | 3,586 | 3,896 | 3,076 | |
Collaborative Arrangements — Net Product Sales ($M)($M) | 4,700 | 4,485 | 4,148 | 3,478 | 3,755 | 3,720 | 3,635 | 3,264 | 3,091 | 3,470 | 3,762 | 2,929 | |
Royalty and Licensing Income (in Other Income/Expense, Net) ($M)($M)9 | 200 | 186 | 195 | 396 | 276 | 162 | 259 | 204 | 180 | 191 | 161 | 420 | |
Keytruda (pembrolizumab) — PD-1 Patent Royalty Income from Merck ($M)($M) | 153 | 149 | 159 | 154 | 150 | 132 | 151 | 139 | 137 | 137 | 133 | 308 | |
Tecentriq (atezolizumab) — PD-L1 Patent Royalty Income from Roche ($M)($M) | 13 | 12 | 14 | 13 | 12 | 11 | 12 | 12 | 12 | 11 | 12 | 29 | |
Other Out-Licensing & Royalty Income ($M)($M) | 22 | 13 | 10 | 218 | 102 | 7 | 43 | 5 | 6 | 6 | 4 | 16 | |
Out-Licensing Upfront & Contingent Milestone Income ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 40 | 36 | 13 | 25 | 0 | 55 | |
Winrevair (sotatercept) — Royalty Revenue Received from Merck (in Other Growth Products) ($M)($M) | 151 | 131 | 124 | 78 | 86 | 78 | 42 | ||||||
Reblozyl (luspatercept) — Royalty Expense Paid to Merck (in COGS) ($M)($M) | 169 | 165 | 124 | 144 | 132 | 122 | 106 | ||||||
Divestiture Royalty Income — Total ($M)($M) | 0 | 0 | 0 | 285 | 286 | 286 | 272 | 284 | 284 | 265 | 271 | 239 | |
Accrued Royalties Payable (Current Liabilities) ($M)($M) | 565 | 552 | 452 | 537 | 513 | 495 | 423 | 477 | 451 | 422 | 371 | 465 | |
Deferred Collaborations & Licensing Income (Noncurrent Liabilities) ($M)($M)1 | 128 | 142 | 155 | 169 | 180 | 197 | 213 | 230 | 247 | 263 | 282 | 300 | |
Amortization of Deferred Collaboration Income Recognized in Revenue ($M)($M) | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | |
Non-GAAP Gross Margin (%)(%)1 | 0.1% | 0.1% | 0.1% | 1.0% | 0.1% | 0.1% | |||||||
GAAP Gross Margin (%)(%) | 68.3% | 71.3% | 70.2% | 71.9% | 72.5% | 72.9% | |||||||
Non-GAAP Cost of Products Sold ($M)($M)2 | 4,133 | 3,711 | 3,408 | 3,312 | 3,356 | 3,018 | |||||||
GAAP Cost of Products Sold ($M)($M) | 4,146 | 3,726 | 3,421 | 4,097 | 3,435 | 3,372 | 3,033 | 4,812 | 2,957 | 3,267 | 2,932 | 2,745 | |
Specified Items in Cost of Products Sold ($M)($M)1 | 13 | 15 | 13 | 589 | 122 | 16 | 14 | 1,600 | 101 | 296 | 22 | 38 | |
Inventory Purchase Price Accounting Adjustments ($M)($M) | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 8 | ||
Non-GAAP Selling, General and Administrative (SG&A) Expense ($M)($M)1 | 1,699 | 1,826 | 1,616 | 2,087 | 1,788 | 1,691 | 1,583 | 2,105 | 1,976 | 1,922 | 1,989 | 2,064 | |
GAAP Selling, General and Administrative Expense ($M)($M) | 1,699 | 1,826 | 1,617 | 2,181 | 1,789 | 1,713 | 1,584 | 2,136 | 1,983 | 1,928 | 2,367 | 2,073 | |
Non-GAAP Research and Development (R&D) Expense ($M)($M)2 | 2,364 | 2,316 | 2,238 | 2,561 | 2,433 | 2,263 | 2,235 | 2,788 | 2,353 | 2,295 | 2,346 | 2,476 | |
GAAP Research and Development Expense ($M)($M) | 2,365 | 2,959 | 2,649 | 2,586 | 2,528 | 2,580 | 2,257 | 3,191 | 2,374 | 2,899 | 2,695 | 2,478 | |
Specified Items in R&D ($M)($M)1 | 1 | 643 | 411 | 25 | 95 | 318 | 21 | 403 | 21 | 604 | 349 | 2 | |
IPR&D Impairments in R&D ($M)($M) | 420 | 410 | 85 | 300 | 390 | 590 | |||||||
Amortization of Acquired Intangible Assets (100% Excluded from Non-GAAP) ($M)($M) | 458 | 437 | 437 | 826 | 831 | 830 | 830 | 1,693 | 2,406 | 2,416 | 2,357 | 2,278 | |
Non-GAAP Other (Income)/Expense, Net ($M)($M)1 | 93 | 126 | 173 | -350 | -206 | -108 | -150 | -53 | -41 | -4 | -154 | -442 | |
Specified Items in Other (Income)/Expense, Net ($M)($M) | 214 | -187 | -140 | 299 | 98 | 602 | 489 | 358 | 275 | 277 | 235 | 71 | |
Non-GAAP Earnings Before Income Taxes ($M)($M)2 | 3,223 | 4,994 | 3,961 | 3,303 | 4,262 | 3,561 | 4,326 | 4,260 | 4,486 | 4,885 | -8,175 | ||
GAAP Earnings/(Loss) Before Income Taxes ($M)($M) | 2,536 | 4,086 | 3,240 | 1,470 | 3,114 | 1,773 | 2,971 | 175 | 1,676 | 1,286 | -11,516 | 1,674 | |
Total Pre-Tax Specified Items (Increase to Pretax Earnings) ($M)($M) | 687 | 908 | 721 | 1,833 | 1,148 | 1,788 | 1,356 | 4,085 | 2,810 | 3,599 | 3,341 | ||
Non-GAAP Income Tax Provision ($M)($M)2 | 456 | 823 | 723 | 730 | 950 | 573 | 652 | 848 | 832 | 689 | 732 | 607 | |
GAAP Income Tax Provision ($M)($M) | 374 | 770 | 561 | 384 | 919 | 460 | 509 | 99 | 461 | -398 | 392 | -88 | |
Income Tax Effect on Specified Items ($M)($M) | 81 | 53 | 161 | 345 | 31 | 114 | 143 | 749 | 371 | 1,087 | 340 | 695 | |
Non-GAAP Effective Tax Rate (%)(%)1 | -0.6% | -2.4% | 0.9% | -4.1% | -7.2% | -9.8% | -2.1% | -36.7% | -9.0% | 45.0% | -5.6% | 20.2% | |
GAAP Effective Tax Rate (%)(%) | 14.8% | 18.8% | 17.3% | 26.2% | 29.5% | 25.9% | 17.1% | 56.6% | 27.5% | -30.9% | -3.4% | -5.3% | |
Non-GAAP Net Earnings Attributable to BMS ($M)($M)2 | 2,767 | 4,172 | 3,237 | 2,574 | 3,318 | 2,985 | 3,668 | 3,408 | 3,650 | 4,192 | -8,910 | ||
GAAP Net Earnings/(Loss) Attributable to BMS ($M)($M) | 2,162 | 3,317 | 2,677 | 1,087 | 2,201 | 1,310 | 2,456 | 72 | 1,211 | 1,680 | -11,911 | 1,762 | |
Total After-Tax Specified Items (Increase to Net Earnings) ($M)($M) | 606 | 855 | 560 | 1,487 | 1,117 | 1,674 | 1,212 | 3,336 | 2,439 | 2,512 | 3,001 | ||
Non-GAAP Diluted Earnings Per Share ($/sh)($)2 | 1.35 | 2.04 | 1.58 | 1.26 | 1.63 | 1.46 | 1.80 | 1.67 | 1.80 | 2.07 | -4.40 | ||
GAAP Diluted Earnings/(Loss) Per Share ($/sh)($) | 1.05 | 1.62 | 1.31 | 0.53 | 1.08 | 0.64 | 1.20 | 0.04 | 0.60 | 0.83 | -5.89 | ||
Specified Items Per Diluted Share ($/sh)($) | 0.30 | 0.42 | 0.27 | 0.73 | 0.55 | 0.82 | 0.59 | 1.63 | 1.20 | 1.24 | 1.49 | ||
GAAP Other (Income)/Expense, Net — Component Breakdown ($M)($M)11 | 307 | -61 | 32 | -51 | -108 | 494 | 339 | 305 | 234 | 273 | 81 | -371 | |
Interest Expense ($M)($M) | 403 | 407 | 411 | 432 | 480 | 485 | 494 | 496 | 505 | 521 | 425 | 316 | |
Investment Income ($M)($M) | -118 | -101 | -104 | -148 | -161 | -139 | -138 | -114 | -94 | -87 | -183 | -145 | |
Royalty and Licensing Income ($M)($M) | -200 | -186 | -195 | -396 | -276 | -162 | -259 | -204 | -180 | -191 | -161 | -420 | |
Royalty Income — Divestitures ($M)($M) | -285 | -286 | -286 | -272 | -284 | -284 | -265 | -271 | -239 | ||||
Provision for Restructuring ($M)($M) | 187 | 56 | 5 | 132 | 75 | 223 | 133 | 77 | 78 | 260 | 220 | 44 | |
Litigation and Other Settlements ($M)($M) | 3 | 5 | 4 | 10 | 165 | 1 | 257 | 13 | 0 | 69 | 2 | 3 | |
Equity Investment (Gains)/Losses, Net ($M)($M) | 26 | -114 | -134 | -190 | -190 | 22 | 78 | 205 | -12 | -107 | -102 | -53 | |
Acquisition Integration Expenses ($M)($M) | 10 | 17 | 19 | 37 | 36 | 32 | 41 | 70 | 69 | 74 | 71 | 62 | |
Divestiture (Gains)/Losses, Net ($M)($M) | -138 | 8 | 1 | ||||||||||
Contingent Consideration Fair Value Adjustments ($M)($M) | 0 | 0 | 15 | 0 | 336 | 0 | 0 | 0 | |||||
Other Miscellaneous (Income)/Expense, Net ($M)($M) | -4 | -6 | 27 | -18 | 40 | -19 | 4 | 46 | 105 | -2 | 31 | 29 | |
Total Restructuring & Exit Charges Across All P&L Lines ($M)($M)11 | 198 | -32 | 1 | 225 | 232 | 279 | 190 | 199 | 263 | 357 | 312 | 128 | |
Provision for Restructuring (in Other Income/Expense, Net) ($M)($M) | 197 | -37 | -1 | 169 | 111 | 255 | 166 | 147 | 147 | 334 | 291 | 106 | |
Restructuring & Site Exit Costs in Cost of Products Sold ($M)($M) | 0 | 2 | 0 | 13 | 110 | 3 | 2 | 8 | 88 | 3 | 14 | 11 | |
Restructuring & Site Exit Costs in Research and Development ($M)($M) | 1 | 3 | 1 | 7 | 10 | 18 | 21 | 13 | 21 | 14 | 1 | 2 | |
Restructuring & Site Exit Costs in SG&A ($M)($M) | 0 | 0 | 0 | 37 | 1 | 3 | 1 | 31 | 7 | 6 | 6 | 9 | |
Employee Termination & Severance Benefits ($M)($M) | 180 | 48 | -2 | 125 | 71 | 220 | 132 | 69 | 77 | 260 | 217 | 41 | |
Accelerated Depreciation of Facilities ($M)($M) | 1 | 0 | 0 | 8 | 9 | 12 | 15 | 20 | 22 | 20 | 14 | 14 | |
Facility & Asset Impairment Charges ($M)($M) | 0 | 1 | 2 | 33 | 111 | 10 | 8 | 8 | 93 | 0 | 2 | 6 | |
Contract Termination Costs ($M)($M) | 6 | 8 | 7 | 7 | 4 | 3 | 1 | 8 | 1 | 0 | 3 | 3 | |
Site Shutdown & Other Exit Costs ($M)($M) | -24 | 16 | 1 | 2 | -7 | 24 | 1 | 3 | 5 | 2 | |||
Strategic Productivity Initiative (2023 Restructuring Plan) — Period Charges ($M)($M)2 | 188 | -49 | -20 | 180 | 193 | 231 | 143 | 91 | 180 | 264 | 68 | 62 | |
2023 Restructuring Plan — Cumulative Costs Incurred to Date ($M)($M) | 1,900 | 1,800 | 1,800 | 1,800 | 1,600 | 1,400 | 1,200 | 1,000 | |||||
2023 Restructuring Plan — Total Expected Program Costs ($M)($M) | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 1,500 | 1,500 | 1,500 | 1,000 | |
Celgene Acquisition & Other Restructuring Plans — Period Charges ($M)($M)1 | 10 | 17 | 21 | 39 | 48 | 47 | 83 | 93 | 244 | ||||
Celgene & Other Restructuring Plans — Remaining Expected Costs ($M)($M) | 30 | 45 | 65 | 90 | 115 | 150 | 200 | 250 | |||||
Restructuring Reserve Liability — Ending Balance ($M)($M)1 | 260 | 150 | 173 | 315 | 287 | 353 | 288 | 297 | 314 | 431 | 309 | 188 | |
Restructuring Cash Payments ( Utilization) ($M)($M) | 76 | 78 | 143 | 106 | 142 | 165 | 145 | 88 | 198 | 137 | 97 | 83 | |
Contingent Value Rights (CVR) Noncurrent Liability ($M)($M) | 607 | 607 | 607 | 607 | 592 | 592 | 256 | 256 | 248 | 248 | 248 | 0 | |
Total Inventories (Current + Noncurrent) ($M)($M)5 | 4,256 | 4,369 | 4,305 | 4,340 | 4,439 | 4,412 | 4,345 | 4,126 | 4,431 | 4,106 | 3,936 | 3,568 | |
Current Inventories, Net ($M)($M) | 2,704 | 2,737 | 2,756 | 2,690 | 2,758 | 2,737 | 2,666 | 2,557 | 3,332 | 3,077 | 2,985 | 2,662 | |
Noncurrent Inventories (Expected to Be Sold Beyond 12 Months) ($M)($M) | 1,552 | 1,632 | 1,549 | 1,650 | 1,681 | 1,675 | 1,679 | 1,569 | 1,099 | 1,029 | 951 | 906 | |
Finished Goods ($M)($M) | 989 | 993 | 894 | 900 | 1,064 | 1,157 | 1,257 | 1,257 | 1,080 | 862 | 885 | 663 | |
Work in Process (WIP) ($M)($M) | 2,894 | 3,035 | 3,101 | 3,159 | 3,063 | 2,916 | 2,768 | 2,549 | 3,008 | 2,807 | 2,496 | 2,430 | |
Raw Materials and Supplies ($M)($M) | 373 | 341 | 310 | 281 | 312 | 339 | 320 | 320 | 343 | 437 | 555 | 475 | |
Property, Plant and Equipment (PP&E), Net ($M)($M)3 | 7,971 | 7,791 | 7,658 | 7,543 | 7,349 | 7,373 | 7,213 | 7,136 | 6,903 | 6,845 | 6,750 | 6,646 | |
Property, Plant and Equipment, Gross ($M)($M)4 | 13,660 | 13,340 | 13,090 | 12,836 | 12,544 | 12,682 | 12,324 | 12,085 | 11,739 | 11,932 | 11,693 | 11,449 | |
Buildings and Improvements, Gross ($M)($M) | 7,972 | 7,933 | 7,486 | 7,270 | 7,124 | 6,855 | 6,640 | 6,581 | 6,470 | 6,670 | 6,546 | 6,495 | |
Machinery, Equipment and Fixtures, Gross ($M)($M) | 4,041 | 3,955 | 3,906 | 3,790 | 3,807 | 3,905 | 3,867 | 3,818 | 3,741 | 3,845 | 3,772 | 3,717 | |
Construction in Progress (CIP), Gross ($M)($M) | 1,483 | 1,296 | 1,541 | 1,619 | 1,456 | 1,761 | 1,656 | 1,525 | 1,367 | 1,255 | 1,213 | 1,075 | |
Land, Gross ($M)($M) | 164 | 157 | 157 | 157 | 157 | 161 | 161 | 161 | 161 | 162 | 162 | 162 | |
Accumulated Depreciation ($M)($M) | 5,688 | 5,549 | 5,431 | 5,293 | 5,195 | 5,309 | 5,111 | 4,949 | 4,836 | 5,087 | 4,943 | 4,803 | |
Depreciation Expense ($M)($M) | 151 | 139 | 139 | 132 | 159 | 165 | 165 | 169 | 166 | 161 | 155 | 163 | |
Goodwill ($M)($M) | 21,735 | 21,740 | 21,740 | 21,754 | 21,745 | 21,776 | 21,737 | 21,719 | 21,751 | 21,732 | 21,738 | 21,169 | |
Other Intangible Assets, Net ($M)($M)8 | 16,936 | 17,387 | 18,244 | 19,103 | 20,465 | 21,378 | 22,486 | 23,307 | 26,964 | 29,428 | 32,760 | 27,072 | |
Other Intangible Assets, Gross ($M)($M) | 71,651 | 71,612 | 72,031 | 72,418 | 73,097 | 73,146 | 73,383 | 73,340 | 75,319 | 75,360 | 76,361 | 68,283 | |
Finite-Lived Intangible Assets — Accumulated Amortization ($M)($M) | 54,715 | 54,226 | 53,786 | 53,315 | 52,632 | 51,768 | 50,897 | 50,033 | 48,355 | 45,932 | 43,601 | 41,211 | |
Marketed Products (Acquired Drug Rights & Patents), Net ($M)($M)2 | 10,954 | 9,030 | 9,384 | 9,739 | 11,036 | 11,773 | 12,490 | 13,217 | 16,387 | 18,747 | 21,357 | 22,892 | |
Marketed Products, Gross ($M)($M) | 63,653 | 61,353 | 61,385 | 61,385 | 61,939 | 61,927 | 61,896 | 61,876 | 63,435 | 63,473 | 63,871 | 63,076 | |
Marketed Products, Accumulated Amortization ($M)($M) | 52,699 | 52,323 | 52,000 | 51,646 | 50,903 | 50,154 | 49,406 | 48,659 | 47,048 | 44,726 | 42,514 | 40,184 | |
Core & Developed Technology, Net ($M)($M)2 | 1,128 | 1,210 | 1,293 | 1,375 | 1,457 | 1,540 | 1,622 | 13,217 | 1,787 | 1,870 | 1,952 | 22,892 | |
Core & Developed Technology, Gross ($M)($M) | 1,980 | 1,980 | 1,980 | 1,980 | 1,980 | 1,980 | 1,980 | 61,876 | 1,980 | 1,980 | 63,076 | ||
Core & Developed Technology, Accumulated Amortization ($M)($M) | 853 | 770 | 688 | 605 | 523 | 440 | 358 | 48,659 | 193 | 110 | 28 | 40,184 | |
Capitalized Software, Net ($M)($M)2 | 384 | 376 | 377 | 389 | 372 | 380 | 389 | 400 | 415 | 436 | 486 | 470 | |
Capitalized Software, Gross ($M)($M) | 1,548 | 1,509 | 1,476 | 1,453 | 1,578 | 1,554 | 1,522 | 1,499 | 1,529 | 1,532 | 1,545 | 1,497 | |
Capitalized Software, Accumulated Amortization ($M)($M) | 1,164 | 1,133 | 1,099 | 1,064 | 1,206 | 1,174 | 1,133 | 1,099 | 1,114 | 1,096 | 1,059 | 1,027 | |
In-Process Research and Development (Indefinite-Lived IPR&D Assets) ($M)($M) | 4,470 | 6,770 | 7,190 | 7,600 | 7,600 | 7,685 | 7,985 | 7,985 | 8,375 | 8,375 | 8,965 | 3,710 | |
Total Intangible Asset Amortization Expense ($M)($M) | 491 | 471 | 472 | 900 | 867 | 864 | 863 | 1,700 | 2,400 | 2,400 | 2,400 | 2,300 | |
Intangible Asset Impairment Charges ($M)($M) | 1,983 | 47 | 27 | ||||||||||
Receivables, Net ($M)($M)2 | 10,639 | 10,553 | 9,368 | 11,414 | 11,422 | 11,415 | 10,801 | 10,747 | 11,026 | 11,423 | 10,447 | 10,921 | |
Trade Accounts Receivable, Gross ($M)($M) | 10,035 | 9,962 | 8,860 | 11,370 | 10,664 | 10,714 | 9,932 | 9,957 | 10,092 | 10,471 | 9,448 | 9,551 | |
Allowance for Expected Credit Losses ($M)($M) | 60 | 59 | 56 | 58 | 52 | 54 | 45 | 45 | 45 | 39 | 24 | 23 | |
Net Debt Position (Cash & Marketable Debt Securities Less Total Debt) ($M)($M)3 | -29,918 | -31,656 | -33,607 | -34,043 | -32,069 | -35,235 | -37,584 | -38,470 | -41,334 | -45,379 | -45,640 | -27,128 | |
Cash, Cash Equivalents and Marketable Debt Securities ($M)($M)3 | 12,959 | 11,464 | 10,853 | 11,069 | 16,909 | 13,950 | 12,126 | 11,179 | 8,418 | 7,010 | 10,037 | 12,644 | |
Cash and Cash Equivalents ($M)($M) | 9,574 | 8,722 | 9,574 | 10,209 | 15,726 | 12,599 | 10,875 | 10,346 | 7,890 | 6,293 | 9,330 | 11,464 | |
Marketable Debt Securities — Current ($M)($M) | 3,007 | 2,345 | 912 | 464 | 776 | 1,004 | 907 | 513 | 204 | 360 | 340 | 816 | |
Marketable Debt Securities — Non-Current ($M)($M) | 378 | 397 | 366 | 396 | 406 | 346 | 344 | 320 | 324 | 357 | 367 | 364 | |
Short-Term Debt Obligations ($M)($M)3 | 1,028 | 1,027 | 2,308 | 2,261 | 4,509 | 4,715 | 3,554 | 2,046 | 1,078 | 3,531 | 6,190 | 3,119 | |
Current Portion of Long-Term Debt ($M)($M) | 768 | 768 | 1,988 | 1,977 | 4,248 | 4,475 | 3,349 | 1,828 | 873 | 3,092 | 2,873 | 2,873 | |
Short-Term Borrowings & Commercial Paper ($M)($M) | 1,028 | 1,027 | 2,308 | 2,261 | 4,509 | 4,715 | 3,554 | 2,046 | 1,078 | 3,531 | 6,190 | 3,119 | |
Other Short-Term Loans ($M)($M) | 260 | 259 | 319 | 284 | 261 | 240 | 205 | 218 | 205 | 173 | 164 | 170 | |
Long-Term Debt (Non-Current) ($M)($M)2 | 41,849 | 42,093 | 42,152 | 42,850 | 44,469 | 44,470 | 46,157 | 47,603 | 48,674 | 48,858 | 49,487 | 36,653 | |
Total Long-Term Debt incl. Current Portion (Carrying Value) ($M)($M) | 42,617 | 42,861 | 44,140 | 44,827 | 48,717 | 48,945 | 49,506 | 49,431 | 49,547 | 51,950 | 52,360 | 39,526 | |
Total Long-Term Debt (Estimated Fair Value) ($M)($M) | 36,000 | 39,200 | 40,200 | 41,500 | 45,800 | 45,500 | 46,000 | 45,300 | 47,900 | 47,700 | 49,200 | 36,700 | |
Operating Lease Right-of-Use (ROU) Assets ($M)($M)1 | 1,480 | 1,486 | 1,528 | 1,582 | 1,604 | 1,276 | 1,215 | 1,224 | 1,348 | 1,316 | 1,436 | 1,390 | |
Total Operating Lease Liabilities ($M)2 | |||||||||||||
Operating Lease Liabilities — Current ($M)($M) | 220 | 207 | 199 | 202 | 214 | 194 | 172 | 181 | 165 | 177 | 169 | 162 | |
Operating Lease Liabilities — Noncurrent ($M)($M) | 1,713 | 1,726 | 1,770 | 1,826 | 1,849 | 1,550 | 1,356 | 1,370 | 1,483 | 1,438 | 1,563 | 1,530 | |
Cash Dividends Paid to Common Shareholders ($M)($M)4 | 1,287 | 1,287 | 1,283 | 1,262 | 1,263 | 1,262 | 1,258 | 1,218 | 1,216 | 1,217 | 1,212 | 1,160 | |
Dividends Declared per Common Share ($/sh)($) | 0.63 | 0.63 | 0.63 | 0.62 | 0.62 | 0.62 | 0.60 | 0.60 | 0.60 | ||||
Common Stock Repurchases — Cash Outflow ($M)($M) | 0 | 0 | 0 | 0 | 0 | ||||||||
Treasury Stock — Carrying Value ($M)($M) | 43,471 | 43,504 | 43,515 | 43,579 | 43,586 | 43,590 | 43,597 | 43,655 | 43,766 | ||||
Stock-Based Compensation Expense — Total ($M)($M)4 | 138 | 135 | 146 | 133 | 139 | 138 | 144 | 120 | 129 | 125 | 133 | 127 | |
Stock-Based Compensation in Research and Development ($M)($M) | 65 | 64 | 72 | 64 | 66 | 66 | 72 | 57 | 62 | 63 | 66 | 61 | |
Stock-Based Compensation in SG&A ($M)($M) | 58 | 56 | 58 | 54 | 58 | 56 | 56 | 48 | 53 | 48 | 53 | 53 | |
Stock-Based Compensation in Cost of Products Sold ($M)($M) | 16 | 15 | 16 | 15 | 16 | 16 | 15 | 15 | 14 | 14 | 14 | 13 | |
Income Tax Benefit Recognized for Stock-Based Compensation ($M)($M) | 30 | 28 | 30 | 27 | 29 | 29 | 30 | 26 | 27 | 27 | 28 | 25 | |
Defined Benefit Pension Plans — Projected Benefit Obligation (PBO) ($M)2 | |||||||||||||
Balance Sheet Noncurrent Pension Assets ($M)($M) | 335 | 332 | 330 | 330 | 281 | 270 | 248 | 234 | 225 | 210 | 290 | 284 | |
Balance Sheet Noncurrent Pension & Postretirement Liability ($M)($M) | 299 | 307 | 317 | 330 | 393 | 415 | 408 | 400 | 447 | 466 | 477 | 480 | |
Earnings/(Loss) Before Income Taxes — Geographic Split ($M)1 | |||||||||||||
Deferred Income Tax Provision/(Benefit) — Total ($M)($M) | -510 | -195 | 161 | -392 | -359 | -437 | 223 | -791 | -256 | -331 | -711 | -1,327 | |
Deferred Tax Assets, Gross (Before Valuation Allowance) ($M)2 | |||||||||||||
Balance Sheet Deferred Income Tax Assets (Noncurrent) ($M)($M) | 5,884 | 5,362 | 5,176 | 5,378 | 4,961 | 4,647 | 3,997 | 4,236 | 3,609 | 3,323 | 2,723 | 2,768 | |
Balance Sheet Deferred Income Tax Liabilities (Noncurrent) ($M)($M) | 228 | 222 | 211 | 222 | 225 | 247 | 276 | 369 | 430 | 461 | 442 | 338 | |
Unrecognized Tax Benefits (UTB) — Ending Balance ($M)2 | |||||||||||||
Income Taxes Payable — Current Liabilities ($M)($M) | 727 | 806 | 909 | 979 | 1,022 | 918 | 1,454 | 1,514 | 1,489 | 1,474 | 1,487 | 1,371 | |
Income Taxes Payable — Noncurrent Liabilities (Transition Tax & UTB) ($M)($M) | 900 | 830 | 1,311 | 1,407 | 1,739 | 1,438 | 1,551 | 1,491 | 1,543 | 1,783 | 3,360 | 3,288 | |
U.S. Personal Consumption Expenditures — Pharmaceutical & Other Medical Products (DHLCRC1Q027SBEA, $B SAAR) | 3,858.70 | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.80 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | |
Consolidated Statements of Earnings — Total Revenues ($M)($M)16 | 13,069 | 12,973 | 11,489 | 12,502 | 12,222 | 12,269 | 11,201 | 12,342 | 11,892 | 12,201 | 11,865 | 11,477 | |
Cost of Products Sold ($M)($M) | 4,146 | 3,726 | 3,421 | 4,097 | 3,435 | 3,372 | 3,033 | 4,812 | 2,957 | 3,267 | 2,932 | 2,745 | |
Research and Development Expense ($M)($M) | 2,365 | 2,959 | 2,649 | 2,586 | 2,528 | 2,580 | 2,257 | 3,191 | 2,374 | 2,899 | 2,695 | 2,478 | |
Selling, General and Administrative Expense ($M)($M) | 1,699 | 1,826 | 1,617 | 2,181 | 1,789 | 1,713 | 1,584 | 2,136 | 1,983 | 1,928 | 2,367 | 2,073 | |
Restructuring Charges ($M)($M) | 187 | 56 | 5 | 131 | 75 | 223 | 133 | 77 | 78 | 260 | 220 | 44 | |
Litigation and Settlement Charges ($M)($M) | -3 | -5 | -4 | -10 | -165 | -1 | -257 | -13 | 0 | -69 | -2 | -3 | |
Total Expenses ($M)($M) | 10,533 | 8,887 | 8,250 | 11,032 | 9,108 | 10,496 | 8,230 | 12,167 | 10,216 | 10,915 | 23,381 | 9,803 | |
Interest Expense ($M)($M) | 403 | 407 | 411 | 432 | 480 | 485 | 494 | 496 | 505 | 521 | 425 | 316 | |
Investment / Interest Income ($M)($M) | 118 | 101 | 104 | 148 | 161 | 139 | 138 | 114 | 94 | 87 | 183 | 145 | |
Earnings/(Loss) Before Income Taxes ($M)($M) | 2,536 | 4,086 | 3,240 | 1,470 | 3,114 | 1,773 | 2,971 | 175 | 1,676 | 1,286 | -11,516 | 1,674 | |
Income Tax Provision/(Benefit) ($M)($M) | 374 | 770 | 561 | 384 | 919 | 460 | 509 | 99 | 461 | -398 | 392 | -88 | |
Net Earnings/(Loss) — Consolidated ($M)($M) | 2,162 | 3,316 | 2,678 | 1,085 | 2,195 | 1,313 | 2,462 | 76 | 1,215 | 1,684 | -11,908 | 1,762 | |
Net Earnings/(Loss) Attributable to BMS ($M)($M) | 2,162 | 3,317 | 2,677 | 1,087 | 2,201 | 1,310 | 2,456 | 72 | 1,211 | 1,680 | -11,911 | 1,762 | |
Basic Earnings/(Loss) Per Share ($/sh)($) | 1.06 | 1.62 | 1.31 | 1.08 | 0.64 | 1.21 | 0.60 | 0.83 | -5.89 | ||||
Diluted Earnings/(Loss) Per Share ($/sh)($) | 1.05 | 1.62 | 1.31 | 1.08 | 0.64 | 1.20 | 0.60 | 0.83 | -5.89 | ||||
Weighted-Average Basic Shares Outstanding (M shares) | 2,043 | 2,042 | 2,038 | 2,036 | 2,035 | 2,031 | 2,028 | 2,027 | 2,023 | ||||
Weighted-Average Diluted Shares Outstanding (M shares) | 2,053 | 2,048 | 2,047 | 2,039 | 2,038 | 2,040 | 2,031 | 2,029 | 2,023 | ||||
Consolidated Balance Sheets — Total Assets ($M)($M)9 | 88,772 | 87,634 | 86,476 | 90,038 | 96,889 | 94,676 | 92,427 | 92,603 | 93,670 | 94,646 | 99,031 | 95,159 | |
Total Current Assets ($M)($M)5 | 29,767 | 28,579 | 27,208 | 29,390 | 35,630 | 33,222 | 30,783 | 29,780 | 28,075 | 26,890 | 28,669 | 31,770 | |
Cash and Cash Equivalents ($M)($M) | 9,574 | 8,722 | 9,574 | 10,209 | 15,726 | 12,611 | 10,875 | 10,347 | 7,893 | 6,296 | 9,334 | 11,519 | |
Marketable Debt Securities — Current ($M)($M) | 3,007 | 2,345 | 912 | 464 | 776 | 1,004 | 907 | 513 | 204 | 360 | 340 | 816 | |
Receivables, Net ($M)($M) | 9,192 | 9,077 | 7,946 | 9,592 | 9,624 | 9,711 | 9,063 | 9,012 | 9,317 | 9,746 | 8,826 | 8,882 | |
Inventories, Current ($M)($M) | 2,704 | 2,737 | 2,756 | 2,690 | 2,758 | 2,737 | 2,666 | 2,557 | 3,332 | 3,077 | 2,985 | 2,662 | |
Other Current Assets ($M)($M) | 3,844 | 4,222 | 4,597 | 4,613 | 4,948 | 5,466 | 5,534 | 5,617 | 5,623 | 5,737 | 5,567 | 5,907 | |
Property, Plant and Equipment, Net ($M)($M) | 7,971 | 7,791 | 7,658 | 7,543 | 7,349 | 7,373 | 7,213 | 7,136 | 6,903 | 6,845 | 6,750 | 6,646 | |
Goodwill ($M)($M) | 21,735 | 21,740 | 21,740 | 21,754 | 21,745 | 21,776 | 21,737 | 21,719 | 21,751 | 21,732 | 21,738 | 21,169 | |
Other Intangible Assets, Net ($M)($M) | 16,936 | 17,387 | 18,244 | 19,103 | 20,465 | 21,378 | 22,486 | 23,307 | 26,964 | 29,428 | 32,760 | 27,072 | |
Marketable Debt Securities — Non-Current ($M)($M) | 378 | 397 | 366 | 396 | 406 | 346 | 344 | 320 | 324 | 357 | 367 | 364 | |
Deferred Income Tax Assets ($M)($M) | 5,884 | 5,362 | 5,176 | 5,378 | 4,961 | 4,647 | 3,997 | 4,236 | 3,609 | 3,323 | 2,723 | 2,768 | |
Other Non-Current Assets ($M)($M) | 6,099 | 6,378 | 6,082 | 6,474 | 6,332 | 5,936 | 5,866 | 6,105 | 6,044 | 6,071 | 6,024 | 5,370 | |
Total Liabilities ($M)($M)3 | 65,368 | 65,315 | 66,374 | 71,533 | 78,289 | 77,187 | 74,979 | 76,215 | 76,470 | 77,577 | 82,483 | 65,674 | |
Total Current Liabilities ($M)($M)3 | 18,753 | 18,659 | 19,158 | 23,417 | 28,136 | 27,528 | 24,070 | 23,774 | 22,638 | 23,265 | 25,822 | 22,262 | |
Short-Term Debt Obligations ($M)($M) | 1,028 | 1,027 | 2,308 | 2,261 | 4,509 | 4,715 | 3,554 | 2,046 | 1,078 | 3,531 | 6,190 | 3,119 | |
Accounts Payable ($M)($M) | 4,628 | 4,158 | 4,234 | 3,575 | 4,288 | 5,427 | 4,002 | 3,602 | 3,469 | 3,751 | 3,539 | 3,259 | |
Other Current Liabilities (incl. Accrued Rebates & Royalties) ($M)($M) | 13,098 | 13,474 | 12,616 | 17,581 | 19,339 | 17,386 | 16,514 | 18,126 | 18,091 | 15,983 | 16,093 | 15,884 | |
Long-Term Debt ($M)($M) | 41,849 | 42,093 | 42,152 | 42,850 | 44,469 | 44,470 | 46,157 | 47,603 | 48,674 | 48,858 | 49,487 | 36,653 | |
Other Non-Current Liabilities ($M)($M) | 4,538 | 4,341 | 4,853 | 5,043 | 5,459 | 4,942 | 4,477 | 4,469 | 4,728 | 4,993 | 6,732 | 6,421 | |
Total Stockholders' Equity ($M)($M)4 | 23,404 | 22,319 | 20,102 | 18,506 | 18,600 | 17,489 | 17,448 | 16,388 | 17,200 | 17,069 | 16,548 | 29,485 | |
Capital in Excess of Par Value of Stock ($M)($M) | 46,674 | 46,504 | 46,374 | 46,387 | 46,265 | 46,134 | 46,011 | 46,024 | 45,896 | 45,766 | 45,655 | 45,684 | |
Retained Earnings ($M)($M) | 21,190 | 20,316 | 18,287 | 16,896 | 17,093 | 16,154 | 16,106 | 14,912 | 16,097 | 16,103 | 15,640 | 28,766 | |
Less: Cost of Treasury Stock ($M)($M) | -43,471 | -43,504 | -43,515 | -43,579 | -43,586 | -43,590 | -43,597 | -43,655 | -43,675 | -43,690 | -43,697 | -43,766 | |
Accumulated Other Comprehensive Loss ($M)($M) | -1,281 | -1,290 | -1,370 | -1,524 | -1,513 | -1,554 | -1,424 | -1,238 | -1,468 | -1,456 | -1,400 | -1,546 | |
Consolidated Statements of Cash Flows — Operating Cash Flow ($M)($M)11 | 4,181 | 3,393 | 1,104 | 1,974 | 6,311 | 3,917 | 1,954 | 4,439 | 5,591 | 2,326 | 2,834 | 4,252 | |
Depreciation and Amortization ($M)($M) | 626 | 594 | 594 | 977 | 1,011 | 1,011 | 1,012 | 1,880 | 2,592 | 2,596 | 2,532 | 2,464 | |
Stock-Based Compensation ($M)($M) | 138 | 135 | 146 | 133 | 139 | 138 | 144 | 120 | 129 | 125 | 133 | 127 | |
Deferred Income Taxes ($M)($M) | -510 | -195 | 161 | -392 | -359 | -437 | 223 | -791 | -256 | -331 | -711 | -1,327 | |
Change in Receivables ($M)($M) | -95 | -1,183 | 1,687 | 19 | 155 | -484 | 15 | 143 | 661 | -1,019 | 479 | -508 | |
Change in Inventories ($M)($M) | 133 | -36 | 14 | 71 | -90 | 4 | -169 | 175 | -218 | -225 | -218 | -197 | |
Change in Accounts Payable ($M)($M) | 252 | -29 | 409 | -90 | 160 | 13 | -85 | 517 | -374 | -259 | 300 | 444 | |
Capital Expenditures (Additions to PP&E and Capitalized Software) ($M)($M) | -344 | -305 | -347 | -370 | -320 | -361 | -260 | -378 | -324 | -262 | -284 | -330 | |
Net Cash Provided by/(Used in) Investing Activities ($M)($M) | -2,104 | -1,614 | -131 | -1,458 | -1,702 | -473 | -499 | -196 | -219 | -1,319 | -19,618 | -1,346 | |
Net Cash Provided by/(Used in) Financing Activities ($M)($M) | -1,222 | -2,630 | -1,560 | -6,029 | -1,490 | -1,836 | -993 | -1,642 | -3,852 | -4,023 | 14,644 | 967 | |
Dividends Paid ($M)($M) | -1,287 | -1,287 | -1,283 | -1,262 | -1,263 | -1,262 | -1,258 | -1,218 | -1,216 | -1,217 | -1,212 | -1,160 | |
Cash Paid for Interest ($M)($M) | 511 | 316 | 473 | 400 | 700 | 376 | 624 | 400 | 665 | 427 | 308 | 268 | |
50 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Bristol-Myers Squibb Company (NYSE: BMY, CIK 0000014272) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026). BMS operates as a single global Biopharmaceuticals operating segment (Note 1), so commercial performance is tracked through Growth Portfolio vs. Legacy Portfolio and brand-level Worldwide / U.S. / International net revenues.
- Core commercial & R&D KPIs (Groups 1–6) cover: (1) Consolidated Revenues ($13,069M in Q3 2026 / $48,194M in FY25 across Net Product Sales $12,606M and Alliance & Other Revenues $463M in Q3 2026; U.S. $9,074M and International $3,995M in Q3 2026; +7% GAAP / +7% Excl. F/X YoY); (2) Growth Portfolio ($7,662M in Q3 2026 / $26,419M in FY25, +12% GAAP / +12% Excl. F/X YoY in Q3 2026: Opdivo $2,374M, Orencia $983M, Yervoy $793M, Reblozyl $750M, Breyanzi $526M, Camzyos $420M, Opdualag $367M, Opdivo Qvantig $334M, Zeposia $168M, Sotyktu $100M, Krazati $58M, Cobenfy $57M, and Other Growth Products $731M, plus historical standalone series for Abecma, Augtyro, Inrebic, Onureg & Empliciti); (3) Legacy Portfolio ($5,415M in Q3 2026 / $21,775M in FY25: Eliquis $4,690M, Revlimid $303M, Pomalyst/Imnovid $130M, Sprycel $73M, Abraxane $65M, Other Legacy Products $154M) and pre-2024 In-Line / New Product / Recent LOE classifications; (4) Gross-to-Net (GTN) reconciliation ($17,965M Gross Product Sales less $5,358M Total GTN Adjustments = $12,606M Net Product Sales in Q3 2026; $88,085M Gross less $41,329M GTN = $46,756M Net in FY25; GTN % dropping from 47% Total / 53% U.S. in FY25 to 30% Total / 32% U.S. in Q3 2026 following the U.S. Eliquis list price cut), 12-year GTN reserve rollforwards ($10,565M ending reserve at FY25), and top-3 U.S. wholesaler concentration (McKesson 31%, Cencora 29%, Cardinal Health 15% of FY25 gross revenues; 83% of Q3 2026 trade AR); (5) R&D by stage ($2,365M GAAP R&D in Q3 2026: Drug Development $1,587M, Research & Discovery $511M, Other R&D $267M), strategic alliances (Pfizer Eliquis $6,980M COGS profit share in FY25; Ono Opdivo; Janssen Milvexian), and patent royalties (Keytruda $166M, Winrevair $151M, Tecentriq $12M received; Reblozyl $169M paid in Q3 2026); and (6) GAAP to Non-GAAP reconciliations (68.4% Non-GAAP Gross Margin, 14.1% Non-GAAP Effective Tax Rate, $1.35 Non-GAAP Diluted EPS in Q3 2026; $6.15 Non-GAAP Diluted EPS in FY25), Specified Items, and Other (Income)/Expense, net components.
- Groups 7–12 cover: (7) Restructuring programs (2023 Strategic Productivity Initiative & Celgene Integration Plan across P&L lines and cost categories; $365M restructuring reserve at Q3 2026) and CVR liabilities; (8) Inventories by stage ($4,524M total inventories at Q3 2026: Current $2,824M, Noncurrent $1,700M; Finished Goods $1,089M, WIP $2,642M, Raw Materials $793M), PP&E by category ($6,456M net at Q3 2026), and Goodwill ($21,546M) & Intangible Assets ($26,876M net at Q3 2026 with 5-year estimated amortization schedule); (9) Net Debt Calculation ($29,918M net debt at Q3 2026: $12,959M cash & marketable debt securities vs. $1,028M short-term debt and $41,849M long-term debt), Operating Leases ($1,558M ROU assets at Q3 2026), Dividends ($0.63/sh declared in Q3 2026), Share Repurchases & Stock-Based Compensation; (10) Defined Benefit Pension ($2,424M PBO / $2,833M plan assets / +$409M funded status at FY25) & OPEB plans and Income Taxes (DTA/DTL & UTB rollforward $1,848M at FY25); (11) Global Workforce (32,500 employees across 43 countries, 54% U.S. in FY25), CEO Pay Ratio (131:1 / $167,191 median employee in FY25), Form 11-K Savings Plans ($12.75B net assets in U.S. SIPS, $203.9M in Puerto Rico Plan, $93.9M in Thrift Plan at FY25), and ESG / Sustainability (Scopes 1, 2 & 3 GHG emissions, energy, 44% renewable electricity share in FY24, water, waste & 0.30 injury rate in FY25); and (12) FRED pharmaceutical industry benchmarks and Consolidated Financial Statements from DB.
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as '>200%' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Dữ liệu cập nhật 2026-11-03.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
1. Consolidated Revenue Composition & Geographic Breakdown (Worldwide / U.S. / International)
2. Growth Portfolio — Brand Net Revenues & YoY Growth by Geography (WW / U.S. / Int'l)
3. Legacy Portfolio & Historical Portfolio Classifications — Brand Net Revenues & YoY Growth
4. Gross-to-Net (GTN) Revenue Adjustments, Reserve Rollforwards & Wholesaler Concentration
5. R&D by Development Stage, Strategic Alliances (Pfizer / Ono / Janssen) & Patent Royalties
6. GAAP to Non-GAAP Reconciliations, Specified Items & Other (Income)/Expense Schedule
- Non-GAAP Gross Margin (%) (%)7 kỳ
- Non-GAAP Cost of Products Sold ($M) ($M)6 kỳ
- Non-GAAP Selling, General and Administrative (SG&A) Expense ($M) ($M)39 kỳ
- Non-GAAP Research and Development (R&D) Expense ($M) ($M)40 kỳ
- Amortization of Acquired Intangible Assets (100% Excluded from Non-GAAP) ($M) ($M)31 kỳ
- Non-GAAP Other (Income)/Expense, Net ($M) ($M)31 kỳ
- Non-GAAP Earnings Before Income Taxes ($M) ($M)12 kỳ
- Non-GAAP Income Tax Provision ($M) ($M)38 kỳ
- Non-GAAP Effective Tax Rate (%) (%)40 kỳ
- Non-GAAP Net Earnings Attributable to BMS ($M) ($M)14 kỳ
- Non-GAAP Diluted Earnings Per Share ($/sh) ($)14 kỳ
- GAAP Other (Income)/Expense, Net — Component Breakdown ($M) ($M)31 kỳ
7. Restructuring Programs (2023 Strategic Productivity Initiative & Celgene Plan), Reserve Rollforward & CVR
8. Inventories by Stage, Property, Plant & Equipment, Goodwill & Intangible Assets
9. Net Debt Position, Debt Maturity Schedule, Operating Leases & Shareholder Capital Return
10. Defined Benefit Pension & Postretirement Plans, Deferred Taxes & Uncertain Tax Positions (UTB)
11. Global Workforce, CEO Pay Ratio (DEF 14A), Form 11-K Savings Plans & ESG / Sustainability
- Total Global Employees (headcount)10 kỳ
- CEO to Median Employee Pay Ratio (times : 1)7 kỳ
- BMS Savings and Investment Program (U.S. 401(k) Plan) — Net Assets Available for Benefits ($K)9 kỳ
- BMS Puerto Rico Savings and Investment Program — Net Assets Available for Benefits ($K)9 kỳ
- BMS Employee Incentive Thrift Plan — Net Assets Available for Benefits ($K)9 kỳ
- Total Value Chain (Scopes 1, 2 & 3) GHG Emissions (mt CO2e)4 kỳ
- Total Energy Consumption (MWh)3 kỳ
- Total Water Withdrawal (million m3 / billion liters)9 kỳ
- Total Operational Waste Generated (metric tons)4 kỳ
- Employee Health & Safety — Recordable Incident / Injury Rate (per 100 employees)8 kỳ
12. U.S. Pharmaceutical Industry Benchmarks (FRED) & Consolidated Financial Statements Context (DB)
- U.S. Producer Price Index — Pharmaceutical Preparation Manufacturing (PCU325412325412, Dec 2003=100)129 kỳ
- U.S. Consumer Price Index — Medical Care Commodities (CUSR0000SAM1, 1982-84=100, SA)128 kỳ
- U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted (MRTSSM44611USS, $M) ($M)128 kỳ
- U.S. Personal Consumption Expenditures — Pharmaceutical & Other Medical Products (DHLCRC1Q027SBEA, $B SAAR)43 kỳ
- Consolidated Statements of Earnings — Total Revenues ($M) ($M)74 kỳ
- Consolidated Balance Sheets — Total Assets ($M) ($M)71 kỳ
- Consolidated Statements of Cash Flows — Operating Cash Flow ($M) ($M)73 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Bristol Myers Squibb
- Form 10-Q (filed 2026-10-29) ↗
- Form 10-K (filed 2026-02-11) ↗
- Form 8-K (a2026q3ex991-filing.htm, filed 2026-10-29) ↗
- Form 8-K (a2025q4ex991.htm, filed 2026-02-05) ↗
- BMS 2025 ESG / Impact Report ↗
- Form 10-K (bmy-20251231.htm, filed 2026-02-11) ↗
- Form 10-K (filed 2024-02-13) ↗
- Form 10-Q (bmy-20260930.htm, filed 2026-10-29) ↗
- Form 8-K (q42019ex991.htm, filed 2020-02-06) ↗
- Proxy Statement (DEF 14A) (bmy-20260325.htm, filed 2026-03-25) ↗
- Form 11-K (BMS Savings Plan) (bmy-20260605.htm, filed 2026-06-05) ↗
- Form 11-K (BMS Savings Plan) (bmy-20260605.htm, filed 2026-06-05) ↗
See a number that looks wrong?